Document:

a08082016exhibit41supple

  EXECUTION VERSION       TALEN ENERGY SUPPLY, LLC (formerly known as PPL Energy Supply, LLC), Issuer TO THE BANK OF NEW YORK MELLON,  Trustee  Supplemental Indenture No. 15 Dated as of August 5, 2016 Supplemental to the Indenture Dated as of October 1, 2001        

 

  SUPPLEMENTAL INDENTURE NO. 15, dated as of August 5, 2016, between TALEN ENERGY SUPPLY, LLC (formerly known as PPL Energy Supply, LLC), a limited liability company duly organized and existing under the laws of the State of Delaware (herein called the “Company”), and THE BANK OF NEW YORK MELLON (as successor to The Chase Manhattan Bank), a New York banking corporation, as Trustee (herein called the “Trustee”), under the Indenture dated as of October 1, 2001 (herein called the “Original Indenture”), this Supplemental Indenture No. 15 being supplemental thereto.  The Original Indenture and any and all indentures and instruments supplemental thereto are herein sometimes collectively called the “Indenture.” Recitals of the Company  The Original Indenture was authorized, executed and delivered by the Company to provide for the issuance by the Company from time to time of its Securities (such term and all other capitalized terms used herein without definition having the meanings assigned to them in the Original Indenture), to be issued in one or more series as contemplated therein.  As contemplated by Sections 301 and 1201(f) of the Original Indenture, the Company previously established a series of Securities designated “Senior Notes, 6.500% Series due 2025” (the “Notes”) pursuant to Supplemental Indenture No. 13, dated as of May 19, 2015, to the Original Indenture (“Supplemental Indenture No. 13”), such series to be limited in aggregate principal amount (except as contemplated in Section 301(b) and the last paragraph of Section 301 of the Original Indenture) to $600,000,000 (such series of Securities herein and in such Supplemental Indenture No. 13 sometimes called “Series No. 11”).  The Company is a wholly owned indirect subsidiary of Talen Energy Corporation, a Delaware corporation (“Talen”).  CRJ Parent LLC, RPH Parent LLC and SPH Parent LLC (collectively, “Parent”), RJS Merger Sub Inc. (“Merger Sub”) and Talen have entered into that certain Agreement and Plan of Merger, dated as of June 2, 2016 (the “Merger Agreement”), pursuant to which Merger Sub, a Delaware corporation and a wholly owned subsidiary of Parent, will merge with and into Talen (the “Merger”), with Talen continuing as the surviving corporation and a wholly owned subsidiary of Parent.  The Merger and the other transactions contemplated by the Merger Agreement are herein referred to as the “Transactions.”   Pursuant to Supplemental Indenture No. 14, dated as of June 2, 2016, to the Original Indenture (“Supplemental Indenture No. 14”), as contemplated by Section 1201(b) of the Original Indenture, the Company provided that, from and after the closing date of the Transactions (the “Trigger Date”), its subsidiaries listed on Schedule A attached hereto (the “Guarantors”) will unconditionally guarantee all of the Company’s obligations under the Securities of Series No. 11 (the “Guarantees”).  The Company desires to revise certain provisions of the Guarantees as set forth in this Supplemental Indenture No. 15.  The Company and the Guarantors have duly authorized the execution and delivery of this Supplemental Indenture No. 15.  All acts necessary to make this Supplemental Indenture No. 15 a valid agreement of the Company and the Guarantors have been performed.  NOW, THEREFORE, THIS SUPPLEMENTAL INDENTURE NO. 15 WITNESSETH:  For and in consideration of the premises set forth herein and in order to enhance the Securities of Series No. 11, it is mutually covenanted and agreed, for the equal and proportionate benefit of all Holders of the Securities of Series No. 11, as follows: 

 

  ARTICLE ONE Amendment to Supplement Indenture No. 14  Section 1. Article One, Section 3(b) of Supplemental Indenture No. 14 is hereby amended and restated in its entirety to read as follows:  (b) Notwithstanding the foregoing and in addition to its other rights hereunder and under the Original Indenture, Supplemental Indenture No. 13 and the Securities of Series No. 11, the Company may elect, in its sole discretion, to release any or all of the Guarantors from their obligations hereunder upon receipt of consent to such release by Holders of the Securities of Series No. 11 constituting at least a majority in aggregate principal amount of the Securities of Series No. 11 then outstanding. ARTICLE TWO Miscellaneous Provisions  Section 1. This Supplemental Indenture No. 15 is a supplement to the Original Indenture, Supplemental Indenture No. 13 and Supplemental Indenture No. 14.  As supplemented by this Supplemental Indenture No. 15, the Indenture is in all respects ratified, approved and confirmed, and the Original Indenture and this Supplemental Indenture No. 15 shall together constitute one and the same instrument.  Section 2. The Company shall not amend, modify or supplement Supplemental Indenture No. 14 or this Supplemental Indenture No. 15 without receipt of consent by Holders of the Securities of Series No. 11 constituting at least a majority, in aggregate principal amount, of the Securities of Series No. 11 then outstanding; it being understood that no such consent shall be required to effectuate any release pursuant to Section 3(a) of Supplemental Indenture No. 14. Section 3. The recitals contained in this Supplemental Indenture No. 15 shall be taken as the statements of the Company and the Trustee assumes no responsibility for their correctness and makes no representations as to the validity or sufficiency of this Supplemental Indenture No. 15.  Section 4. This Supplemental Indenture shall be governed by, and construed in accordance with the laws of the State of New York, without regard to the provisions thereof relating to conflict of laws. Section 5. This instrument may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument. 

 

 

 

 

 

 

 

 

  SCHEDULE A GUARANTORS Talen Investment Corporation Raven Lot 15 LLC Talen Generation, LLC Raven FS Property Holdings LLC Susquehanna Nuclear, LLC Fort Armistead Road – Lot 15 Landfill, LLC Martins Creek, LLC H.A. Wagner LLC Brunner Island, LLC Brandon Shores LLC Pennsylvania Mines, LLC Jade Power Generation Holdings LLC Montour, LLC C/R Topaz Holdings, LLC Lower Mount Bethel Energy, LLC Topaz Power Group GP II, LLC Raven Power Generation Holdings, LLC Topaz Power Group LP II, LLC Raven Power Finance LLC Barney M. Davis, LP Raven Power Operating LLC Laredo WLE, LP Raven Power Marketing LLC Nueces Bay WLE, LP Raven Power Fort Smallwood LLC Talen Energy Marketing, LLC Topaz Power Holdings, LLCEX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

ARDELYX, INC. 

SECURITIES PURCHASE AGREEMENT 

This Securities Purchase Agreement (“Agreement”) is made as of July 14, 2016 (the “Effective Date”), by
and among Ardelyx, Inc., a Delaware corporation (the “Company”), each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the
“Schedule of Purchasers”) and Future Fund Investment Company No. 4 Pty Ltd, a proprietary limited company organized under the laws of Australia (the “FF Beneficial Investor”). 

The persons and entities listed as Purchasers on the Schedule of Purchasers are hereinafter collectively referred to herein as
“Purchasers” and each individually as a “Purchaser.” The Purchasers and the FF Beneficial Investor shall herein be collectively referred to as the “Investors” and each as an
“Investor”. “FF Investor” means The Northern Trust Company, an Illinois company, in its capacity as custodian for the FF Beneficial Investor. 

AGREEMENT 
 In
consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company, and each Investor (severally and not jointly) hereby agree as follows: 

SECTION 1. AUTHORIZATION OF SALE OF THE SHARES. 

The Company has authorized the sale and issuance of 12,600,230 shares of its Common Stock, par value $0.0001 per share (the “Common
Stock”), on the terms and subject to the conditions set forth in this Agreement. The shares of Common Stock sold hereunder at the Closing (as defined below) shall be referred to as the “Shares.” 

SECTION 2. AGREEMENT TO SELL AND PURCHASE THE SHARES. 

2.1 Sale of Shares. At the Closing (as defined in Section 3), the Company will sell to each Purchaser, and each Purchaser
will purchase from the Company, the number of Shares set forth opposite such Purchaser’s name on the Schedule of Purchasers at a purchase price of $8.73 per Share. The aggregate purchase price for the Shares purchased by each Purchaser is set
forth opposite such Purchaser’s name on the Schedule of Purchasers. 
 2.2 Separate Agreement. Each Purchaser shall
severally, and not jointly, be liable for only the purchase of the Shares that appear on the Schedule of Purchasers that relate to such Purchaser. The Company’s agreement with each of the Investors, is a separate agreement, and the sale of
Shares to each of the Purchasers is a separate sale. The obligations of each Investor hereunder are expressly not conditioned on the purchase by any or all of the other Purchasers of the Shares such other Purchasers have agreed to purchase. 

 SECTION 3. CLOSING AND DELIVERY. 

3.1 Closing. The closing of the purchase and sale of the Shares (which Shares are set forth in the Schedule of Purchasers)
pursuant to this Agreement (the “Closing”) shall be held on July 18, 2016 at the offices of Latham & Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, or on such other date and place as may be agreed to by
the Company and the Purchasers (the “Closing Date”). At or prior to the Closing, each Investor shall execute any related agreements or other documents required to be executed hereunder, dated on or before the Closing Date. 

3.2 Issuance of the Shares at the Closing. At the Closing, the Company shall issue or deliver to each Purchaser evidence of a
book entry position (or, if requested in writing by a Purchaser on or before the date hereof, a certificate) evidencing the Shares purchased by such Purchaser hereunder, registered in the name of such Purchaser, or in such nominee name(s) as
designated by such Purchaser, representing the number of Shares to be purchased by such Purchaser at such Closing as set forth in the Schedule of Purchasers against payment of the purchase price for such Shares; provided, that with respect to
any certificates evidencing Shares issued, the Company will confirm ownership of the Shares represented by such certificate on the Closing Date with the physical certificate representing such Shares to be delivered promptly thereafter. The name(s)
in which the Shares are to be issued to each Purchaser are set forth in the Purchaser Questionnaire and the Selling Stockholder Notice and Questionnaire in the form attached hereto as Appendices I and II (the “Purchaser
Questionnaire” and the “Selling Stockholder Questionnaire,” respectively), as completed by each Investor, which shall be provided to the Company no later than the Closing Date. 

3.3 Delivery of the Registration Rights Agreement. At or before the Closing, the Company and each Investor shall execute and
deliver the Registration Rights Agreement in the form attached hereto as Appendix III (the “Registration Rights Agreement”), with respect to the registration of the Shares under the Securities Act of 1933, as amended (the
“Securities Act”). 
 3.4 Delivery of the FF Side Letter. At or before the Closing, the Company, the FF Investor and
the FF Beneficial Investor shall execute and deliver the FF Side Letter (the “FF Side Letter”). 
 SECTION 4. REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE COMPANY. 
 Except as set forth on the Schedule of Exceptions delivered to the Purchasers
concurrently with the execution of this Agreement (the “Schedule of Exceptions”) or as otherwise described in the SEC Documents (as defined below), which disclosures qualify these representations and warranties in their entirety,
the Company hereby represents and warrants as of the date hereof, and covenants with, the Investors as follows: 
 4.1 Organization and
Standing. The Company (a) has been duly incorporated and is validly existing as a corporation in good standing under the laws of Delaware with full corporate power and authority to own or lease, as the case may be, and to operate its
properties and conduct its business as presently conducted, and (b) is duly qualified to do business as a foreign 

  
 2 

 
corporation and is in good standing under the laws of each jurisdiction which requires such qualification, except in the case of clause (b) above, to the extent that the failure to be so
qualified or be in good standing would not reasonably be expected to result in (i) a material adverse effect on the validity or enforceability of this Agreement, (ii) a material adverse effect on the condition (financial or otherwise),
earnings, business or properties of the Company, or (iii) a material adverse effect on the Company’s ability to perform in any material respect its obligations under this Agreement (any condition that would be reasonably expected to result
in any of clauses (i), (ii) or (iii), a “Material Adverse Effect”). The Company has no subsidiaries. 
 4.2
Corporate Power; Authorization. The Company has all requisite corporate power and authority, and has taken all requisite corporate action, to execute and deliver this Agreement, the Registration Rights Agreement, the FF Side Letter
(the Registration Rights Agreement and the FF Side Letter, collectively with the Agreement, the “Transaction Documents”), sell and issue the Shares and carry out and perform all of its obligations under the Transaction Documents.
Each Transaction Document constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by equitable principles generally, including any specific performance and (iii) with respect to the Registration Rights Agreement, as rights to
indemnity or contribution may be limited by state or federal laws or public policy underlying such laws. 
 4.3 Issuance and Delivery of
the Shares. The Shares have been duly authorized and, when issued and paid for in compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable and free of any security interest, lien, pledge,
claim, charge, escrow, encumbrance, right of first offer, right of first refusal, preemptive right, mortgage, indenture, security agreement or other restriction (“Encumbrance”) other than restrictions on transfer under the
Transaction Documents, applicable state and federal securities laws and Encumbrances created by or imposed by the Investors. Assuming the accuracy of the representations made by each Purchaser in Section 5 and the FF Beneficial Investor in
Section 14.14, the offer and issuance by the Company of the Shares is exempt from registration under the Securities Act. 
 4.4 SEC
Documents; Financial Statements. The Company has filed in a timely manner all documents that the Company was required to file with the Securities and Exchange Commission (the “Commission”) under Sections 13, 14(a) and
15(d) the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since becoming subject to the requirements of the Exchange Act. As of their respective filing dates (or, if amended prior to the date of this Agreement,
when amended), all documents filed by the Company with the Commission (the “SEC Documents”) complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated
thereunder. None of the SEC Documents as of their respective dates contained any untrue statement of material fact or omitted to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the
circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Documents (the “Financial Statements”) present fairly the financial condition, results of operations and cash
flows of the Company as of the dates and for the periods indicated, comply as to form with the applicable accounting requirements of 

  
 3 

 
the Exchange Act (including Regulation S-X thereunder) and have been prepared in conformity with United States generally accepted accounting principles applied on a consistent basis throughout
the periods involved (except as otherwise expressly noted therein). Ernst & Young LLP, who have certified certain financial statements of the Company, delivered their report with respect to the audited financial statements and schedules
included in the SEC Documents, are independent public accountants with respect to the Company within the meaning of the Exchange Act and the applicable published rules and regulations thereunder. 

4.5 Capitalization. The authorized capital stock of the Company consists of 300,000,000 shares of common stock and 5,000,000
shares of undesignated Preferred Stock. As of the Effective Date, there are no shares of Preferred Stock issued and outstanding and there are 34,650,266 shares of Common Stock issued and outstanding, of which no shares are owned by the Company.
There are no other shares of any other class or series of capital stock of the Company issued or outstanding. The Company has no capital stock reserved for issuance, except that, as of the Effective Date, there are (i) 3,937,733 shares of
Common Stock reserved for issuance pursuant to the Company’s stock incentive plans, of which 2,506,834 shares are issuable upon the exercise of stock options outstanding on the date hereof and 65,753 shares are issuable upon the vesting of
restricted stock units outstanding on the date hereof, (ii) 313,062 shares of Common Stock reserved for issuance pursuant to the Company’s employee stock purchase plan and (iii) 2,172,899 shares of Common Stock reserved for issuance
upon the exercise of outstanding warrants. There are no bonds, debentures, notes or other indebtedness having general voting rights (or convertible into securities having such rights) (“Voting Debt”) of the Company issued and
outstanding. Except as stated above, there are no existing options, warrants, calls, subscriptions or other rights, agreements, arrangements or commitments relating to the issued or unissued capital stock of the Company, obligating the Company
to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred, sold, redeemed, purchased, repurchased or otherwise acquired any capital stock or Voting Debt of, or other equity interest in, the
Company or securities or rights convertible into or exchangeable for such shares or equity interests or obligations of the Company to grant, extend or enter into any such option, warrant, call, subscription or other right, agreement, arrangement or
commitment. The issuance of Common Stock or other securities pursuant to any provision of this Agreement will not give rise to any preemptive rights or rights of first refusal on behalf of any Person or result in the triggering of any
anti-dilution rights. Other than the Amended and Restated Investors’ Rights Agreement dated June 23, 2011 by and among the Company and the parties listed therein, the Registration Rights Agreement dated June 2, 2015 by and among the
Company and the other parties thereto and the Controlled Equity OfferingSM Sales Agreement dated July 13, 2015 between the Company and Cantor Fitzgerald & Co., there are no
agreements or arrangements under which the Company is obligated to register the sale of any of its securities under the Securities Act. 

4.6 Litigation. No action, suit, investigation, debarment process or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or its property is pending or, to the best knowledge of the Company, threatened that will have a Material Adverse Effect, whether or not arising from transactions in the ordinary course of
business. 

  
 4 

 4.7 Governmental Consents. No consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any federal, state, or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement
or the Registration Rights Agreement except for (a) the filing of a Form D with the Commission under the Securities Act and compliance with the securities and blue sky laws in the states and other jurisdictions in which shares of Common Stock
are offered and/or sold, which compliance will be effected in accordance with such laws, (b) the approval by the NASDAQ Global Market of the listing of the Shares and (c) the filing of one or more registration statements and all amendments
thereto with the Commission as contemplated by the Registration Rights Agreement. 
 4.8 No Default or Consents. Neither the
execution, delivery or performance of the Transaction Documents by the Company nor the consummation of any of the transactions contemplated thereby (including, without limitation, the issuance and sale by the Company of the Shares) will conflict
with, result in a breach or violation of, or imposition of any lien, charge or Encumbrance upon any property or assets of the Company pursuant to, (i) the certificate of incorporation or by-laws of the Company, (ii) the terms of any
indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party or bound or to which its or their property is subject, or
(iii) any statute, law, rule, regulation, judgment, order or decree applicable to the Company of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any of
its properties, except in the case of clauses (ii) and (iii) above, for any conflict, breach or violation of, or imposition that would not have a Material Adverse Effect. 

4.9 No Material Adverse Change. Since March 31, 2016, there have not been any changes in the authorized capital, assets,
liabilities, financial condition, business, Material Agreements or operations of the Company from that reflected in the Financial Statements except changes in the ordinary course of business which have not been, either individually or in the
aggregate, materially adverse to the business, properties, financial condition or results of operations of the Company. 
 4.10 No
General Solicitation. Neither the Company nor any Person acting on its behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act) in connection
with the offer or sale of the Shares. 
 4.11 No Integrated Offering. Neither of the Company or any Person acting on its
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) of the Securities Act
or require registration of any of the Shares under the Securities Act or cause this offering of the Shares to be integrated with prior offerings by the Company for purposes of the Securities Act. 

4.12 Sarbanes-Oxley Act. There is and has been no failure on the part of the Company and any of the Company’s directors or
officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including, without limitation, Section 402 relating to loans.

  
 5 

 4.13 Intellectual Property. The Company owns, possesses, licenses or has other
rights to use, on reasonable terms, all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual property
(collectively, the “Intellectual Property”) necessary for the conduct of the Company’s business as now conducted or as proposed in the SEC Documents to be conducted (the “Company Intellectual Property”). To the
knowledge of the Company, there are no rights of third parties to any Company Intellectual Property, other than as licensed by the Company. To the knowledge of the Company, there is no infringement by third parties of any Company Intellectual
Property. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s rights in or to any Company Intellectual Property. There is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any Company Intellectual Property. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others
that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others. The Company is not aware of any facts required to be disclosed to the U.S. Patent and Trademark Office
(“USPTO”) which have not been disclosed to the USPTO and which would preclude the grant of a patent in connection with any patent application of the Company Intellectual Property or could form the basis of a finding of invalidity
with respect to any issued patents of the Company Intellectual Property. 
 4.14 Compliance with NASDAQ Continued Listing
Requirements. The Company is in compliance with applicable NASDAQ continued listing requirements. There are no proceedings pending or, to the Company’s knowledge, threatened against the Company relating to the continued listing of
the Common Stock on NASDAQ and the Company has not received any notice of, nor to the Company’s knowledge is there any reasonable basis for, the delisting of the Common Stock from NASDAQ. 

4.15 Disclosure. The Company understands and confirms that the Investors will rely on the foregoing representations in effecting
transactions in securities of the Company. To the knowledge of the executive officers of the Company, all due diligence materials regarding the Company, its business and the transactions contemplated hereby, furnished by or on behalf of the
Company to the Purchasers (other than the FF Investor) and to the FF Beneficial Investor are, when taken together with the Schedule of Exceptions, true and correct in all material respects and do not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. 

4.16 Contracts. Each franchise, contract or other document of a character required to be described in the SEC Documents or to be
filed as an exhibit to the SEC Documents under the Securities Act and the rules and regulations promulgated thereunder (collectively, the “Material Contracts”) is so described or filed. 

  
 6 

 4.17 Properties and Assets. The Company owns or leases all such properties as are
necessary to the conduct of its operations as presently conducted. 
 4.18 Compliance. Except as would not result in a
Material Adverse Effect: (i) the Company is and has been in compliance with statutes, laws, ordinances, rules and regulations applicable to the Company for the ownership, testing, development, manufacture, packaging, processing, use, labeling,
storage, or disposal of any product manufactured by or on behalf of the Company or out-licensed by the Company (a “Company Product”), including without limitation, the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301, et
seq., the Public Health Service Act, 42 U.S.C. § 262, similar laws of other governmental entities and the regulations promulgated pursuant to such laws (collectively, “Applicable Laws”); (ii) the Company possesses all
licenses, certificates, approvals, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws and/or for the ownership of its properties or the conduct of its business as it relates to a Company Product and as
described in the SEC Documents (collectively, “Authorizations”) and such Authorizations are valid and in full force and effect and the Company is not in violation of any term of any such Authorizations; (iii) the Company has
not received any written notice of adverse finding, warning letter or other written correspondence or notice from the U.S. Food and Drug Administration (the “FDA”) or any other governmental entity alleging or asserting noncompliance
with any Applicable Laws or Authorizations relating to a Company Product; (iv) the Company has not received written notice of any ongoing claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any
governmental entity or third party alleging that any Company Product, operation or activity related to a Company Product is in violation of any Applicable Laws or Authorizations or has any knowledge that any such governmental entity or third party
is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, nor, to the Company’s knowledge, has there been any noncompliance with or violation of any Applicable Laws by the Company that would reasonably
be expected to require the issuance of any such written notice or result in an investigation, corrective action, or enforcement action by the FDA or similar governmental entity with respect to a Company Product; (v) the Company has not received
written notice that any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations or has any knowledge that any such governmental entity has threatened or is considering such action
with respect to a Company Product; and (vi) the Company has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable
Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete, correct and not misleading on the date filed (or were corrected or supplemented by a
subsequent submission). To the Company’s knowledge, neither the Company nor any of its directors, officers, employees or agents, has made, or caused the making of, any false statements on, or material omissions from, any other records or
documentation prepared or maintained to comply with the requirements of the FDA or any other governmental entity. 
 4.19
Taxes. The Company has filed all tax returns that are required to be filed or has requested extensions thereof (except in any case in which the failure so to file would not have a Material Adverse Effect, whether or not arising from
transactions in the ordinary course of business, except as contemplated in the SEC Documents) and has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the

  
 7 

 
foregoing is due and payable, except for any such assessment, fine or penalty that is currently being contested in good faith or as would not have a Material Adverse Effect, whether or not
arising from transactions in the ordinary course of business, except as contemplated in the SEC Documents. 
 4.20 Transfer
Taxes. There are no transfer taxes or other similar fees or charges under Federal law or the laws of any state, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement or
the issuance by the Company or sale by the Company of the Shares. 
 4.21 Investment Company. The Company is not, and, after
giving effect to the offering and sale of the Shares, will not be, an “investment company” as defined in the Investment Company Act of 1940, as amended. 

4.22 Insurance. The Company is insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are reasonable and customary in the business in which it is engaged; all policies of insurance and fidelity or surety bonds insuring the Company or its businesses, assets, employees, officers and directors are in full force and
effect; the Company is in compliance with the terms of such policies and instruments in all material respects; and there are no claims by the Company under any such policy or instrument as to which any insurance company is denying liability or
defending under a reservation of rights clause; the Company has not been refused any insurance coverage sought or applied for; and the Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect, whether or not arising from transactions in the ordinary course of
business. 
 4.23 Price of Common Stock. The Company has not taken, directly or indirectly, any action designed to cause or
result in, or that has constituted or that might reasonably be expected to constitute the stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale of the Shares. 

4.24 Governmental Permits, Etc. The Company possesses all licenses, certificates, permits and other authorizations issued by all
applicable authorities necessary to conduct its business, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if
the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect, whether or not arising from transactions in the ordinary course of business. 

4.25 Internal Control over Financial Reporting; Sarbanes-Oxley Matters. The Company maintains a system of internal accounting
controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any 

  
 8 

 
differences. The Company’s internal controls over financial reporting are effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles and the Company is not aware of any material weakness in its internal controls over financial reporting. The Company maintains “disclosure
controls and procedures” (as such term is defined in Rule 13a-15(e) under the Exchange Act); such disclosure controls and procedures are effective. 

4.26 Foreign Corrupt Practices. The Company is not nor, to the knowledge of the Company, any director, officer, agent, or
employee of the Company is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the
“FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or
other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign
political office, in contravention of the FCPA; and the Company. 
 4.27 Labor. No labor problem or dispute with the employees
of the Company exists or, to the knowledge of the Company, is threatened, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its principal suppliers or contractors, that could have a Material
Adverse Effect, whether or not arising from transactions in the ordinary course of business, except as contemplated in the SEC Documents. 

4.28 ERISA. None of the following events has occurred or exists: (i) a failure to fulfill the obligations, if any, under
the minimum funding standards of Section 302 of the United States Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and the regulations and published interpretations thereunder with respect to a Plan that
is required to be funded, determined without regard to any waiver of such obligations or extension of any amortization period; (ii) an audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit
Guaranty Corporation or any other federal or state governmental agency or any foreign regulatory agency with respect to the employment or compensation of employees by any of the Company that could have a Material Adverse Effect; (iii) any
breach of any contractual obligation, or any violation of law or applicable qualification standards, with respect to the employment or compensation of employees by the Company that would reasonably be expected to have a Material Adverse Effect. None
of the following events has occurred or is reasonably likely to occur: (i) a material increase in the aggregate amount of contributions required to be made to all Plans in the current fiscal year of the Company compared to the amount of such
contributions made in the most recently completed fiscal year of the Company; (ii) a material increase in the “accumulated post-retirement benefit obligations” (within the meaning of Statement of Financial Accounting Standards 106) of
the Company compared to the amount of such obligations in the most recently completed fiscal year of the Company; (iii) any event or condition giving rise to a liability under Title IV of ERISA that could have a Material Adverse Effect; or
(iv) the filing of a claim by one or more employees or former employees of the Company related to their employment that could have a Material Adverse Effect. For purposes of this paragraph, the term “Plan” means a plan (within the
meaning of Section 3(3) of ERISA) subject to Title IV of ERISA with respect to which the Company may have any liability. 

  
 9 

 4.29 Environmental Laws. The Company (i) is in compliance with any and all
applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”),
(ii) has received and is in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct its business and (iii) has not received notice of any actual or potential liability under
any environmental law, except where such non-compliance with Environmental Laws, failure to receive required permits, licenses or other approvals, or liability would not, individually or in the aggregate, have a Material Adverse Effect, whether or
not arising from transactions in the ordinary course of business. The Company has not been named as a “potentially responsible party” under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended. 

4.30 Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements and the money laundering statutes and the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency
(collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is
pending or, to the knowledge of the Company, threatened. 
 4.31 OFAC. Neither the Company nor, to the knowledge of the
Company, any director, officer, agent or employee of the Company (i) is currently subject to any sanctions administered or imposed by the United States (including any administered or enforced by the Office of Foreign Assets Control of the U.S.
Treasury Department, the U.S. Department of State, or the Bureau of Industry and Security of the U.S. Department of Commerce), the United Nations Security Council, the European Union, or the United Kingdom (including sanctions administered or
controlled by Her Majesty’s Treasury) (such sanctions, collectively, “Sanctions” and such persons, collectively, “Sanction Persons”) or (ii) will, directly or indirectly, use the proceeds of this offering,
or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person in any manner that will result in a violation of any economic Sanctions by, or could result in the imposition of Sanctions
against, any person (including any person participating in the offering, whether as underwriter, advisor, investor or otherwise). Neither the Company nor, to the knowledge of the Company, any director, officer, agent, or employee of the Company is a
person that is, or is 50% or more owned or otherwise controlled by a person that is: (x) the subject of any Sanctions; or (y) located, organized or resident in a country or territory that is, or whose government is, the subject of
Sanctions that broadly prohibit dealings with that country or territory (currently, Cuba, Iran, North Korea, Sudan, and Syria) (collectively, “Sanctioned Countries” and each, a “Sanctioned Country”). Except as has
been disclosed to the Purchasers (other than the FF Investor) and the FF Beneficial Investor, or is not material to the analysis under any Sanctions, the Company has not engaged in any dealings or transactions with or for the benefit of a Sanctioned
Person, or with or in a Sanctioned Country, in the preceding three years, nor does the Company have any plans to increase its dealings or transactions with Sanctioned Persons or with or in Sanctioned Countries. 

  
 10 

 4.32 Compliance in Clinical Trials. The clinical studies and tests conducted by the
Company or on behalf of the Company, have been and, if still pending, are being conducted in all material respects pursuant to all Applicable Laws and Authorizations; the descriptions of the results of such clinical studies and tests contained in
the SEC Documents are accurate and complete in all material respects and fairly present the data derived from such clinical studies and tests; the Company is not aware of any clinical studies or tests, the results of which the Company believes
reasonably call into question the research, nonclinical or clinical study or test results described or referred to in the SEC Documents when viewed in the context in which such results are described; and the Company has not received any written
notices or correspondence from any governmental entity requiring the termination, suspension or material modification of any clinical study or test conducted by or on behalf of the Company. 

SECTION 5. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASERS. 

5.1 Each Purchaser (other than the FF Investor for the purposes of Sections 5.1(b), 5.1(c), 5.1(d), 5.1(k), 5.1(h)(i), 5.1(h)(ii), 5.1(h)(v),
5.1(p) and 5.1(q) and the second and third sentence of Section 5.1(f)), severally and not jointly, represents and warrants to and covenants with the Company that: 

(a) Such Purchaser (if an entity) is a validly existing corporation, limited partnership, limited liability company, trust, pension plan, or
government plan and has all requisite corporate, partnership, limited liability company or other requisite organizational power and authority to enter into and consummate the transactions contemplated by the Transaction Documents and to carry out
its obligations hereunder and thereunder, and to invest in the Shares pursuant to this Agreement. 
 (b) Such Purchaser acknowledges that it
can bear the economic risk and complete loss of its investment in the Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby. 

(c) Such Purchaser has had an opportunity to receive, review and understand all information related to the Company requested by it and to ask
questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares, and has conducted and completed its own independent due diligence. Such Purchaser acknowledges that the
Company has made available the SEC Documents. Based on the information such Purchaser has deemed appropriate, and without reliance upon any placement agent, it has independently made its own analysis and decision to enter into the Transaction
Documents. Such Purchaser is relying exclusively on the contents of the Transaction Documents and its own sources of information, investment analysis and due diligence (including professional advice it deems appropriate) with respect to the
execution, delivery and performance of the Transaction Documents, the Shares and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all business, legal,
regulatory, accounting, credit and tax matters. 

  
 11 

 (d) The Shares to be received by such Purchaser hereunder will be acquired for such
Purchaser’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act. 

(e) Such Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the
Securities Act without prejudice, however, to such Purchaser’s right at all times to sell or otherwise dispose of all or any part of such Shares in compliance with applicable federal and state securities laws. 

(f) Such Purchaser is not a broker-dealer registered with the Commission under the Exchange Act or an entity engaged in a business that would
require it to be so registered. Such Purchaser understands that the Shares are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not
involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances. Purchaser will not, directly or indirectly, offer,
sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the securities purchased hereunder except in compliance with the Securities Act, applicable blue sky laws, and
the rules and regulations promulgated thereunder. 
 (g) Such Purchaser is an “accredited investor” within the meaning of Rule
501(a) under the Securities Act. 
 (h) Such Purchaser has determined based on its own independent review and such professional advice as it
deems appropriate that its purchase of the Shares and participation in the transactions contemplated by the Transaction Documents (i) are fully consistent with its financial needs, objectives and condition, (ii) comply and are fully
consistent with all investment policies, guidelines and other restrictions applicable to such Purchaser, (iii) have been duly authorized and approved by all necessary action, (iv) do not and will not violate or constitute a default under
such Purchaser’s charter, by-laws or other constituent document or, to the extent defaults would have a material effect on the Purchaser’s ability to perform its obligations under this Agreement, under any law, rule, regulation, agreement
or other obligation by which such Purchaser is bound and (v) are a fit, proper and suitable investment for such Purchaser, notwithstanding the substantial risks inherent in investing in or holding the Shares. 

(i) The execution, delivery and performance by such Purchaser of the Transaction Documents to which such Purchaser is a party have been duly
authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation of such Purchaser, enforceable against such Purchaser in accordance with their respective terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally. 

  
 12 

 (j) Such Purchaser is not a broker or dealer registered pursuant to Section 15 of the
Exchange Act (a “registered broker-dealer”). Purchaser is not party to any agreement for distribution of any of the Shares. 

(k) Such Purchaser shall have completed or caused to be completed and delivered to the Company at no later than the Closing Date, the
Purchaser Questionnaire and the Selling Stockholder Questionnaire for use in preparation of the registration statement meeting the requirements set forth in the Registration Rights Agreement and covering the resale by the Purchasers of the
Registrable Securities (as defined in the Registration Rights Agreement) (the “Registration Statement”), and the answers to the Purchaser Questionnaire and the Selling Stockholder Questionnaire are true and correct in all material
respects as of the date of this Agreement and will be true and correct as of the Closing and the effective date of the Registration Statement; provided, that the Purchasers shall be entitled to update such information by providing notice
thereof to the Company before the effective date of such Registration Statement. 
 (l) Such Purchaser understands that no United States
federal or state agency, or similar agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of the Shares. 

(m) Such Purchaser has no present intent to effect a “change of control” of the Company as such term is understood under the rules
promulgated pursuant to Section 13(d) of the Exchange Act. 
 (n) Such Purchaser has not taken any of the actions set forth in, or is
not subject to, the disqualification provisions of Rule 506(d)(1) of the Securities Act. 
 (o) Such Purchaser did not learn of the
investment in the Shares as a result of any general solicitation or general advertising. 
 (p) Such Purchaser’s residence (if an
individual) or offices in which its investment decision with respect to the Shares was made (if an entity) are located at the address immediately below such Purchaser’s name on its signature page hereto. 

(q) Such Purchaser (including any person controlling, controlled by, or under common control with such Purchaser, as the term
“control” is defined pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and its implementing regulations (the “HSR Act”)) in connection with the consummation of the transactions contemplated
by this Agreement will not be required to and will not complete a filing with the U.S. government pursuant to the HSR Act. 
 5.2 Other than
consummating the transactions contemplated hereunder, such Purchaser has not, nor has any person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including all
“short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock) (“Short Sales”), of the securities of
the Company during the period commencing as of the time that such Purchaser was first contacted by the Company or any other person regarding the transactions contemplated 

  
 13 

 
hereby and ending immediately prior to the Effective Date. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set
forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement. Other than to other persons party to this Agreement, such
Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein
shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. 

5.3 Purchaser understands that nothing in this Agreement or any other materials presented to Purchaser in connection with the purchase and
sale of the Shares constitutes legal, tax or investment advice. Purchaser has, or, in the case of the FF Investor, the FF Beneficial Investor has, consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary
or appropriate in connection with its purchase of the Shares. 
 5.4 Legends. 

(a) Purchaser understands that, until such time as the Shares have been sold pursuant to the Registration Statement or the Shares may be sold
pursuant to Rule 144 under the Securities Act (“Rule 144”) without any restriction as to the number of securities as of a particular date that can then be immediately sold, the certificate or book entry notations evidencing the
Shares may bear one or more legends in substantially the following form and substance: 
 “THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF
THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND IN THE CASE OF A TRANSACTION
EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS.”

  
 14 

 In addition, certificates or book entry notations representing the Shares may contain: 

(i) Any legend required by the laws of the State of California, including any legend required by the California Department of Corporations.

 (ii) Any legend required by the blue sky laws of any other state to the extent such laws are applicable to the sale of such Shares
hereunder. 
 (iii) A legend regarding affiliate status of the Purchasers set forth in Schedule 1 hereto, in the form included therein. 

(b) The Company agrees that at such time as such legend is no longer required under this section, it will, no later than three business days
following the delivery by a Purchaser to the Company or the Company’s transfer agent of a certificate representing Shares, and if such Shares are certificated, issued with a restrictive legend, together with such representations and covenants
of such Purchaser or such Purchaser’s executing broker as the Company may reasonably require in connection therewith, deliver or cause to be delivered to such Purchaser a book entry position representing such shares that is free from any legend
referring to the Securities Act. The Company shall not make any notation on its records or give instructions to any transfer agent of the Company that enlarge the restrictions on transfer set forth in this section. To the extent that certificates or
book entry positions are issued representing the Shares, such certificates or book entry positions subject to legend removal hereunder shall be transmitted by the transfer agent of the Company to the Purchasers by crediting the account of such
Purchaser’s prime broker with the Depository Trust Company (“DTC”). All costs and expenses related to the removal of the legends and the reissuance of any Shares shall be borne by the Company. 

(c) The restrictive legend set forth in this section above shall be removed and the Company shall issue a certificate or book entry position
without such restrictive legend or any other restrictive legend to the holder of the applicable shares upon which it is stamped or issue to such holder by electronic delivery with the applicable balance account at DTC or in physical certificated
shares, if appropriate, if (i) such Shares are registered for resale under the Securities Act (provided that, if the Purchaser is selling pursuant to an effective registration statement registering the Shares for resale, the Purchaser
agrees to only sell such Shares during such time that such registration statement is effective and such Purchaser is not aware or has not been notified by the Company that such registration statement has been withdrawn or suspended, and only as
permitted by such registration statement); (ii) such Shares are sold or transferred pursuant to Rule 144 (if the transferor is not an affiliate of the Company); or (iii) such Shares are eligible for sale without the requirement for the
Company to be in compliance with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions. Subject to receipt of such representations, and covenants as are contemplated hereby,
following the earlier of (i) the effective date of the Registration Statement or (ii) Rule 144 becoming available for the resale of the Shares, without the requirement for the Company to be in compliance with the current public information
required under Rule 144 as to the Shares and without volume or manner-of-sale restrictions, the Company shall issue to the Company’s transfer agent the instructions with respect to legend removal consistent with this section. Any fees (with
respect to the transfer agent, the Company’s counsel or otherwise) associated with the issuance of such opinion or the removal of such legend shall be borne by the Company. 

  
 15 

 5.5 Restricted Shares. Purchaser understands that the Shares are characterized as
“restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such Shares may be resold
without registration under the Securities Act only in certain limited circumstances. In this connection, such Purchaser represents that it is familiar with Rule 144, as presently in effect, and understands the resale limitations imposed thereby and
by the Securities Act. 
 5.6 Exculpation Among Purchasers. Purchaser acknowledges that it is not relying upon any other
Purchaser, or any officer, director, employee, agent, partner, member or affiliate of any such other Purchaser, in making its investment or decision to invest in the Company. Purchaser agrees that neither any Purchaser nor the respective controlling
Persons, officers, directors, partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the purchase of the Shares. 

SECTION 6. CONDITIONS TO COMPANY’S OBLIGATIONS AT THE CLOSING. 

Without prejudice to Section 8.1 in the case of the sale, issuance and delivery of Shares to the FF Investor, the Company’s
obligation to complete the sale and issuance of the Shares and deliver Shares to each Purchaser, individually, as set forth in the Schedule of Purchasers at the Closing shall be subject to the following conditions to the extent not waived by the
Company: 
 6.1 Receipt of Payment. The Company shall have received payment, by wire transfer of immediately available funds,
in the full amount of the purchase price for the number of Shares being purchased by such Purchaser at the Closing as set forth in the Schedule of Purchasers. 

6.2 Representations and Warranties. The representations and warranties made by the Purchasers in Section 5 hereof shall be
true and correct in all material respects when made, and shall be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and as of said date. The Purchaser shall have performed in all
material respects all obligations and covenants herein required to be performed by them on or prior to the Closing Date. 
 6.3 Receipt
of Executed Documents. Such Purchaser shall have executed and delivered to the Company the Registration Rights Agreement, the Purchaser Questionnaire and the Selling Stockholder Questionnaire. 

  
 16 

 SECTION 7. CONDITIONS TO PURCHASERS’ OBLIGATIONS AT THE CLOSING. 

Without prejudice to Section 8.2 in the case of FF Investor, each Purchaser’s obligation to accept delivery of the Shares and to pay
for the Shares shall be subject to the following conditions to the extent not waived by such Purchaser: 
 7.1 Representations and
Warranties. The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all material respects as of, and as if made on, the date of this Agreement and as of the Closing Date, except
to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date. 

7.2 Performance. The Company shall have performed in all material respects all obligations and covenants herein required to be
performed by it on or prior to the Closing Date.  
 7.3 Receipt of Executed Registration Rights Agreement. The Company shall
have executed and delivered to the Purchasers the Registration Rights Agreement. 
 7.4 Legal Opinion. The Investors shall
have received an opinion of Latham & Watkins LLP, special counsel to the Company, dated as of the Closing Date, in form and substance reasonably acceptable to the Investors. 

7.5 Certificate. Each Purchaser shall have received a certificate signed by the Chief Executive Officer or the Chief Financial
Officer to the effect that the representations and warranties of the Company in Section 4 hereof are true and correct in all material respects as of, and as if made on, the date of this Agreement and as of the Closing Date and that the Company
has satisfied in all material respects all of the conditions set forth in this Section 7. 
 7.6 Good Standing. The
Company is validly existing as a corporation in good standing under the laws of Delaware. 
 7.7 Nasdaq Approval. The Company
shall have filed with NASDAQ a Notification Form: Listing of Additional Shares for the listing of the Shares. 
 7.8
Judgments. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued,
and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby. 

7.9 Stop Orders. No stop order or suspension of trading shall have been imposed by the NASDAQ Global Market, the Commission or
any other governmental regulatory body with respect to public trading in the Common Stock (any such order or suspension, a “Suspension”). 

SECTION 8. ADDITIONAL CONDITIONS TO SALE OF SHARES TO THE FF INVESTOR. 

8.1 Without prejudice to Section 6, the Company’s obligation to complete the sale and issuance of the Shares and deliver Shares to
the FF Investor, as set forth in the Schedule of Purchasers at the Closing shall be subject to the following conditions unless waived by the Company: 

(a) Receipt of Executed Documents. The FF Beneficial Investor and the FF Investor shall have executed and delivered to the Company the
FF Side Letter. The FF Beneficial Investor shall have executed and delivered to the Company the Registration Rights Agreement, the Purchaser Questionnaire and the Selling Stockholder Questionnaire. 

  
 17 

 (b) Representations and Warranties. The representations and warranties made by the FF
Beneficial Investor in Section 14.14 hereof shall be true and correct in all material respects when made, and shall be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and
as of said date. The FF Beneficial Investor shall have performed in all material respects all obligations and covenants herein required to be performed by them on or prior to the Closing Date. 

8.2 Without prejudice to Section 7, the FF Investor’s obligation to accept delivery of the Shares set forth in the Schedule of
Purchasers at the Closing and to pay for the Shares shall be subject to the Company having executed and delivered to the FF Investor and the FF Beneficial Investor the FF Side Letter. 

SECTION 9. TERMINATION OF OBLIGATIONS TO EFFECT CLOSING; EFFECTS. 

9.1 This Agreement may be terminated, on a Purchaser-by-Purchaser basis, as follows: 

(a) upon the mutual written consent of the Company and such Purchaser; 

(b) by the Company if any of the conditions set forth in Sections 6 and 8.1 (as applicable to such Purchaser) shall have become incapable
of fulfillment, and shall not have been waived by the Company or satisfied by September 30, 2016; or 
 (c) by such Purchaser if any of
the conditions set forth in Sections 7 and 8.2 (as applicable to such Purchaser) shall have become incapable of fulfillment, and shall not have been waived by the Purchaser or satisfied by September 30, 2016; 

provided, however, that, except in the case of clauses (b) and (c) above, the party seeking to terminate its obligation to effect the
Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving rise to such party’s
seeking to terminate its obligation to effect the Closing. 
 9.2 If this Agreement is terminated by either the Company or a Purchaser
pursuant to the provisions of Section 9.1, this Agreement with respect to the Company and such Purchaser shall (and, in the case of the FF Investor, the FF Beneficial Investor) forthwith become void and there shall be no further obligations on
the part of the Company or such Purchaser (and, in the case of the FF Investor, the FF Beneficial Investor) or their respective stockholders, directors, officers, employees, agents or representatives, except for rights and obligations that had
accrued hereunder prior to such termination and the provisions of Sections 11.6 with respect to the Confidentiality Obligations (as defined below), 11.7, 12, 13 and 14, which shall survive any termination of this Agreement; provided, that
nothing in this Section 8 shall be deemed (i) to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents, or (ii) to impair the right of any
party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents, in either case, which may have arisen prior to termination of this Agreement. 

  
 18 

 SECTION 10. BROKER’S FEES. 

The Company and each Purchaser (severally and not jointly), other than the FF Investor, hereby represent that there are no brokers or finders
entitled to compensation, commissions, placement agent’s fees or similar payments in connection with the sale of the Shares, and shall indemnify each other for any such fees for which they are responsible. 

SECTION 11. ADDITIONAL AGREEMENTS OF THE PARTIES. 

11.1 NASDAQ Listing. The Company will use commercially reasonable efforts to continue the listing and trading of its Common Stock
on the NASDAQ Global Market and, in accordance, therewith, will use commercially reasonable efforts to comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of such market or exchange, as
applicable. 
 11.2 Access to Information. From the date hereof until the Closing, the Company will make reasonably available
to the Investors’ representatives, consultants and their respective counsels for inspection, such information and documents as the Investor reasonably requests, and will make available at reasonable times and to a reasonable extent officers and
employees of the Company to discuss the business and affairs of the Company. 
 11.3 Termination of Covenants. The provisions of
Sections 11.1-11.2 shall terminate and be of no further force and effect on the date on which the Company’s obligations under the Registration Rights Agreement to register or maintain the effectiveness of any registration covering the
Registrable Shares (as such term is defined in the Registration Rights Agreement) shall terminate. 
 11.4 Form D; Blue Sky
Filings. The Company agrees to timely file a Form D with respect to the Shares and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is
necessary in order to obtain an exemption for, or to qualify the Shares for, sale to the Purchaser at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions
promptly upon request of any Purchaser. 
 11.5 Integration. The Company shall not, and shall use its commercially reasonable
efforts to ensure that no affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or
sale of the Shares in a manner that would require the registration under the Securities Act of the sale of the Shares to the Purchasers, or that will be integrated with the offer or sale of the Shares for purposes of the rules and regulations of any
trading market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. 

  
 19 

 11.6 Short Sales and Confidentiality After the Date Hereof. Each Purchaser
covenants that neither it nor any affiliates acting on its behalf or pursuant to any understanding with it will execute any Short Sales during the period from the date hereof until the earlier of such time as (i) after the transactions
contemplated by this Agreement are first publicly announced or (ii) this Agreement is terminated in full. Except (x) as required by applicable law or the listing rules of any applicable national or regional securities exchange, (y) as
required to be disclosed in filings or other submissions to any court, regulatory body, administrative agency, governmental body, arbitrator or other legal authority having jurisdiction over a party hereto made to obtain necessary consents,
approvals or filings, or (z) as provided by the terms and provisions of the existing confidentiality and non-use obligations of the parties hereto, or as provided in the FF Side Letter, each Purchaser covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company, such Purchaser will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this
transaction) (such obligations, the “Confidentiality Obligations”). Each Purchaser understands and acknowledges that the Commission currently takes the position that coverage of short sales of shares of the Common Stock
“against the box” prior to effectiveness of a resale registration statement with securities included in such registration statement would be a violation of Section 5 of the Securities Act, as set forth in Item 239.10 of the
Securities Act Rules Compliance and Disclosure Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance. 

11.7 Securities Laws Disclosure; Publicity. By 5:00 P.M., New York City time, on the trading day immediately following the
Effective Date, the Company shall issue a press release disclosing the material terms of the transactions contemplated hereby. On or before 9:00 A.M., New York City time, on the third trading day immediately following the execution of this
Agreement, the Company will file a Current Report on Form 8-K (the “8-K”) with the Commission describing the material terms of the Transaction Documents (and including as exhibits to such Current Report on Form 8-K the
agreements required to be filed in connection therewith). Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Investor, or include the name of any Investor in any public filing with the Commission or any regulatory
agency or NASDAQ, without the prior written consent of such Investor, which consent shall not be unreasonably withheld, conditioned or delayed, except: (a) as required by federal securities law in connection with (i) any registration
statement contemplated by the Registration Rights Agreement and (ii) the filing of final Transaction Documents with the Commission; (b) the filing of a Form D with the Commission under the Securities Act and (c) to the extent such
disclosure is required by law or NASDAQ regulations, in which case the Company shall provide the Investor with prior notice of such disclosure permitted under this clause (c). As of the time of the filing of the 8-K, no Investor shall be in
possession of any material, non-public information received from the Company, any subsidiary of the Company or any of their respective officers, directors, employees or agents, pursuant to the transactions contemplated by this Agreement that is not
disclosed in the 8-K, press release or other disclosure by the Company that complies with the requirements of Regulation FD.
 11.8
Confirmation of Securities Holdings. Upon request of an Investor, as long as such Investor is a record holder of the Shares, the Company will use commercially reasonable efforts to cause the transfer agent of the Shares to provide
confirmation of such Investor’s Common Stock holdings. 

  
 20 

 SECTION 12. INDEMNIFICATION. 

12.1 Indemnification by the Company. The Company agrees to indemnify and hold harmless each of the Investors, the officers,
directors, partners, members, and employees of each Purchaser, each Person who controls any such Investor (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, partners,
members and employees of each such controlling Person (each, an “Indemnified Party”), against any losses, claims, damages, liabilities or expenses, joint or several, to which such Indemnified Party may become subject under the
Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such
losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based in whole or in part on the inaccuracy in the representations and warranties of the Company contained in this Agreement
or the failure of the Company to perform its obligations hereunder, and will reimburse each Indemnified Party for legal and other expenses reasonably incurred as such expenses are reasonably incurred by such Indemnified Party in connection with
investigating, defending, settling, compromising or paying such loss, claim, damage, liability, expense or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage,
liability or expense arises out of or is based upon (i) the failure of such Indemnified Party to comply with the covenants and agreements contained in Sections 5 and 11.6 above respecting sale of the Shares, or (ii) the inaccuracy of any
representations made by such Indemnified Party herein. 
 12.2 Indemnification by Investors. Each Investor shall severally,
and not jointly, indemnify and hold harmless the other Purchasers and the Company, its directors, officers, and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the
Exchange Act) and the directors, officers, partners, members or employees of such controlling Persons, against any losses, claims, damages, liabilities or expenses to which the Company, each of its directors or each of its controlling Persons may
become subject, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent
of such Investor) insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based upon (i) any failure by such Investor to comply with the covenants and agreements
contained in Sections 5 and 11.6 above respecting the sale of the Shares unless such failure by such Investor is directly caused by the Company’s failure to provide written notice of a Suspension to such Investor or (ii) the inaccuracy of
any representation made by such Investor herein, in each case to the extent, and will reimburse the Company, each of its directors, and each of its controlling Persons for any legal and other expense reasonably incurred, as such expenses are
reasonably incurred by the Company, each of its directors, and each of its controlling Persons in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. No Investor
shall be liable for the indemnification obligations of any other Investor. 

  
 21 

 SECTION 13. NOTICES. 

All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or mailed
by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or
courier, and addressed as follows: 
 if to the Company, to: 

Ardelyx, Inc. 
 34175 Ardenwood
Blvd., Suite 200 
 Fremont, California 94555 

Attention: Chief Executive Officer 

E-Mail: mraab@ardelyx.com 
 with
a copy (which shall not constitute notice) to: 
 Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park,
California 94025 
 Attention: Mark Roeder 

E-Mail: mark.roeder@lw.com 
 or
to such other person at such other place as the Company shall designate to the Investors in writing; and 
 if to the Investors, at the
address as set forth at the end of this Agreement, or at such other address or addresses as may have been furnished to the Company in writing. 
 SECTION
14. MISCELLANEOUS. 
 14.1 Waivers and Amendments. Neither this Agreement nor any provision hereof may be changed,
waived, discharged, terminated, modified or amended with respect to the Company and a Purchaser only with the written consent of the Company and such Purchaser and, in the case, of the FF Investor, the Beneficial Investor. 

14.2 Headings. The headings of the various sections of this Agreement have been inserted for convenience of reference only and
shall not be deemed to be part of this Agreement. 
 14.3 Severability. In case any provision contained in this Agreement
should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. 

14.4 Replacement of Shares. If the Shares are certificated and any certificate or instrument evidencing any Shares is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence

  
 22 

 
reasonably satisfactory to the Company and the Company’s transfer agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit
of that fact and an agreement to indemnify and hold harmless the Company and the Company’s transfer agent for any losses in connection therewith or, if required by the transfer agent, a bond in such form and amount as is required by the
transfer agent. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Shares. If a replacement certificate or instrument
evidencing any Shares is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement. 

14.5 Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under this Agreement are several
and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under this Agreement. Nothing contained herein and no action taken by any Investor
pursuant hereto, shall be deemed to constitute the Investor as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group, or are deemed
affiliates (as such term is defined under the Exchange Act) with respect to such obligations or the transactions contemplated by this Agreement. Each Investor shall be entitled to independently protect and enforce its rights, including without
limitation the rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. 

14.6 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction
Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the
interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or
agents) shall be commenced exclusively in the state and federal courts sitting in the City of San Francisco. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City San Francisco for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any other manner permitted by law. 
 14.7 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute 

  
 23 

 
but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event that any signature is delivered
by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force
and effect as if such facsimile of “.pdf” signature were the original thereof. 
 14.8 Successors and Assigns.
Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 

14.9 Entire Agreement. This Agreement and other documents delivered pursuant hereto, including the exhibit and the Schedule of
Exceptions, and, in the case of the FF Beneficial Investor and the Company, the FF Side Letter, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. As among the Company, the
FF Investor and the FF Beneficial Investor, the provisions of the FF Side Letter will prevail over the provisions of this Agreement to the extent of any inconsistency. 

14.10 Payment of Fees and Expenses. Each of the Company and the Investors shall bear its own expenses and legal fees incurred on
its behalf with respect to this Agreement and the transactions contemplated hereby. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable
attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
 14.11
Survival. The representations, warranties, covenants and agreements made in this Agreement shall survive any investigation made by the Company or the Investors and the Closing. 

14.12 Waiver of Potential Conflicts of Interest. Each of the Investors and the Company acknowledges that Latham & Watkins
LLP (“Latham”) may have represented and may currently represent certain of the Investors. In the course of such representation, Latham may have come into possession of confidential information relating to such Investors. Each of the
Investors and the Company acknowledges that Latham is representing only the Company in this transaction. By executing this Agreement, each of the Investors and the Company hereby waives any actual or potential conflict of interest which has or may
arise as a result of Latham’s representation of such persons and entities, and represents that it has had the opportunity to consult with independent counsel concerning the giving of this waiver. 

14.13 Assignment. The rights of the FF Investor hereunder may be assigned in whole or in part to a Permitted Transferee (as defined in
the FF Side Letter) (but only with all restrictions and obligations set forth in this Agreement); provided, however, (i) the FF Investor shall, within five (5) days prior to such assignment, furnish to the Company written
notice of the name and address of such Permitted Transferee, details of its status as a Permitted Transferee and details of the Registrable Securities with respect to which such registration rights are being assigned, (ii) the Permitted
Transferee, prior to or simultaneously with such transfer or assignment, shall agree in writing to be subject to and bound by all restrictions and obligations set forth in this 

  
 24 

 
Agreement, and (iii) such transfer or assignment shall be effective only if immediately following such transfer or assignment the further disposition of such Registrable Securities by the
Permitted Transferee is restricted under the Securities Act and other applicable securities laws. 
 14.14 Representations and Warranties
of the FF Beneficial Investor. The FF Beneficial Investor represents and warrants to the Company that each of the representations and warranties made by the Purchasers in Section 5 (other than those in Section 5.1(p)), substituting
references to “Purchaser” with “FF Beneficial Investor”, are true and correct as of the date hereof and shall be true and correct as of the Closing; provided that, in the case of Section 5.1(k), the FF Beneficial Investor
gives this representations and warranties set out there only in respect of FF Beneficial Investor’s completion and delivery of, and answers to, the Purchaser Questionnaire and the Selling Stockholder Questionnaire and, for the avoidance of
doubt, not the FF Investor’s completion, delivery and answers; provided further that the FF Beneficial Investor represents and warrants to the Company that the FF Beneficial Investor’s offices in which its investment decision with respect
to the Shares was made are located at the address indicated for the FF Beneficial Investor in the Purchaser Questionnaire delivered by the FF Beneficial Investor. The FF Investor hereby represents that it is acquiring the Shares as custodian for the
FF Beneficial Investor and not with a view to, or for sale in connection with, the distribution thereof within the meaning of the Securities Act. 

14.15 FF Investor Limitation of Liability. The FF Investor enters into and is liable under (a) this Agreement, (b) any other
document or agreement which the FF Investor may provide under this Agreement (including without limitation the Registration Rights Agreement and the FF Side Letter) and (c) any document or agreement executed by the Company or any other person
as agent or attorney of the FF Investor under this Agreement only in its capacity as custodian for the FF Beneficial Investor and to the extent that it is actually indemnified by the FF Beneficial Investor. To the extent this paragraph operates to
reduce the amounts for which the FF Investor would otherwise be liable to any person, the FF Beneficial Investor will pay or procure the payment of such amounts to such person. 

[Signature pages follow] 

  
 25 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	ARDELYX, INC.
		
	By:	 	 /s/ Michael Raab

	Name:	 	Michael Raab
	Title:	 	President and Chief Executive Officer

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written 
  

					
		  	     PURCHASER:
  

	 EXECUTED on behalf of THE NORTHERN TRUST COMPANY (ABN 62 126 279 918), a company incorporated in the State of Illinois in the United
States of America, in its capacity as custodian for Future Fund Investment Company No.4 Pty Ltd, by
  

Jonathan Carstens
 being a person who, in accordance with the laws
of that territory, is acting under the authority of the company in the presence of:
  

/s/ Stephen Dyason
  

Signature of witness
  

STEPHEN DYASON
  

 
 Name of witness (block letters)

Level 43, 120 Collins St,
 Melbourne, VIC, 3000 Australia.

 
  

Address of witness
  

Date: July 15, 2016
	  	 )
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
  

)
	 	 /s/ Jonathan Carstens
  

By executing this agreement the signatory warrants that the signatory is duly authorized to execute this agreement on behalf of THE NORTHERN TRUST
COMPANY

			
		  		 	Address:
			
		  		 	The Northern Trust Company
		  		 	Level 47, 80 Collins Street
		  		 	Melbourne VIC 3000 Australia

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

							
		 	 PURCHASERS:

    FF BENEFICIAL INVESTOR:

				
		 	Signed for and on behalf of Future Fund Investment Company No. 4 Pty Ltd by:	 		 	
				
		 	 Paul Mann
	 		 	 /s/ Paul Mann

		 	Name of Director	 		 	 Signature of Director
 15/7/16

				
		 	  
  
	 		 	  
 Date

		
		 	 Address:

		
		 	 Future Fund Investment Company No. 4 Pty Ltd

Level 43, 120 Collins Street

Melbourne VIC 3000 Australia

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	New Enterprise Associates 12, Limited Partnership
		
	By:	 	 /s/ Louis S. Citron

	Name:	 	 Louis S. Citron

	Title:	 	 Chief Legal Officer

			
		
	Address:	 	 c/o New Enterprise Associates

	 1954 Greenspring Drive, Suite 600

	 Timonium, MD 21093

	Email:	 	 ####@NEA.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	NEA 15 Opportunity Fund, L.P.
		
	By:	 	 /s/ Louis S. Citron

	Name:	 	 Louis S. Citron

	Title:	 	 Chief Legal Officer

			
		
	Address:	 	 c/o New Enterprise Associates

	 1954 Greenspring Drive, Suite 600

	 Timonium, MD 21093

	Email:	 	 ####@NEA.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	New Enterprise Associates 15, L.P.
		
	By:	 	 /s/ Louis S. Citron

	Name:	 	 Louis S. Citron

	Title:	 	 Chief Legal Officer

			
		
	Address:	 	 c/o New Enterprise Associates

	 1954 Greenspring Drive, Suite 600

	 Timonium, MD 21093

	Email:	 	 ####@NEA.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	EcoR1 Capital Fund Qualified, LP
		
	By:	 	 /s/ Oleg Nodelman

	Name:	 	 Oleg Nodelman

	Title:	 	 Manager, EcoR1 Capital LLC, GP

			
		
	Address:	 	 409 Illinois Street

	 San Francisco, CA 94158

	Email:	 	 ####@ecor1cap.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	EcoR1 Capital Fund, LP
		
	By:	 	 /s/ Oleg Nodelman

	Name:	 	 Oleg Nodelman

	Title:	 	 Manager, EcoR1 Capital LLC, GP

			
		
	Address:	 	 409 Illinois Street

	 San Francisco, CA 94158

	Email:	 	 ####@ecor1cap.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	Quadrille Ardelyx, LLC
		
	By:	 	 /s/ Jerome Chevalier

	Name:	 	 Jerome Chevalier

	Title:	 	 Partner

 
			
		
	Address:	 	 c/o Quadrille Capital

	 16 Place de la Madeleine

	 75008 Paris

	 France

	Email:	 	  

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	Cormorant Global Healthcare Maser Fund, LP
	
	 /s/ Bihua Chen

	By:	 	 Cormorant Gobal Healthcare GP, LLC

	Name:	 	 Bihua Chen, Managing Member of the
GP

 
			
		
	Address:	 	 200 Clarendon Street, 52nd Floor

	 Boston, MA 02116

	Email:	 	 ####@cormorant-asset.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	CRMA SPV, L.P.
	
	 /s/ Bihua Chen

	By:	 	 Cormorant Asset Management, LLC

	Name:	 	 Bihua Chen, Managing Member of the Special

	 Limited Partner

			
		
	Address:	 	 PO Box 309

	 Ugland House

	 Grand Cayman

	 KY1-1104 Cayman Islands

	Email:	 	 ####@cormorant-asset.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	Rock Springs Capital Master Fund LP
		
	By:	 	Rock Springs General Partner LLC
		
	By:	 	 /s/ Kris H. Jenner

	Name:	 	 Kris H. Jenner

	Title:	 	 Managing Member

			
		
	Address:	 	 650 S. Exeter Street, Ste 1070

	 Baltimore, MD 21202

	Email:	 	 ####@rockspringcapital.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
		
	By:	 	RA Capital Management, LLC
	Its:	 	General Partner

 
			
		
	By:	 	 /s/ Nicholas McGrath

	Name:	 	 Nicholas McGrath

	Title:	 	 Authorized Signatory

			
		
	Address:	 	 20 Park Plaza, Suite 1200

	 Boston, MA 02116

	Email:	 	  

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	Blackwell Partners LLC – Series A
		
	By:	 	 /s/ Abayomi A. Adigun

	Name:	 	 Abayomi A. Adigun

	Title:	 	 Investment Advisor

	 DUMAC, Inc., Authorized Agent

		
	By:	 	 /s/ Jannine M. Lall

	Name:	 	 Jannine M. Lall

	Title:	 	 Controller

	 DUMAC, Inc., Authorized
Agent

 
			
		
	Address:	 	 DUMAC, Inc.

	 280 S. Mangum Street, Suite 210

	 Durham, NC 27701

	Email:	 	 ####@dumac.edu

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
		
	By:	 	Deerfield Mgmt, L.P.
		 	General Partner
		 	By: J.E. Flynn Capital, LLC
		 	        General Partner

 
			
		
	By:	 	 /s/ David J. Clark

	Name:	 	 David J. Clark

	Title:	 	 Authorized Signatory

			
		
	Address:	 	 780 Third Avenue, 37th Floor

	 New York, NY 10017

	Email:	 	 ####@deerfield.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	DAFNA LifeScience LP
		
	By:	 	 /s/ Fariba Ghodsian

	Name:	 	 Fariba Ghodsian

	Title:	 	 C.I.O.

 
			
		
	Address:	 	 10990 Wilshire Boulevard, Suite 1400

	 Los Angeles, CA 90024

	Email:	 	 ####@DAFNACapital.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	DAFNA LifeScience Select LP
		
	By:	 	 /s/ Fariba Ghodsian

	Name:	 	 Fariba Ghodsian

	Title:	 	 C.I.O.

 
			
		
	Address:	 	 10990 Wilshire Boulevard, Suite 1400

	 Los Angeles, CA 90024

	Email:	 	 ####@DAFNACapital.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	First BioMed, L.P.
		
	By:	 	 /s/ Neal K. Stearns

	Name:	 	 Neal K. Stearns

	Title:	 	 Senior Managing Director

			
		
	Address:	 	 399 Park Avenue

	 New York, NY 10022

	Email:	 	  

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	First Health, L.P.
		
	By:	 	 /s/ Neal K. Stearns

	Name:	 	 Neal K. Stearns

	Title:	 	 Senior Managing Director

			
		
	Address:	 	 399 Park Avenue

	 New York, NY 10022

	Email:	 	  

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	First BioMed Portfolio, L.P.
		
	By:	 	 /s/ Neal K. Stearns

	Name:	 	 Neal K. Stearns

	Title:	 	 Senior Managing Director

 

			
	Address:	 	 399 Park Avenue

	 New York, NY 10022

	Email:	 	  

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	First Health Limited
		
	By:	 	 /s/ Neal K. Stearns

	Name:	 	 Neal K. Stearns

	Title:	 	 Senior Managing Director

			
		
	Address:	 	 399 Park Avenue

	 New York, NY 10022

	Email:	 	  

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	First Health Associates, L.P.
		
	By:	 	 /s/ Neal K. Stearns

	Name:	 	 Neal K. Stearns

	Title:	 	 Senior Managing Director

			
		
	Address:	 	 399 Park Avenue

	 New York, NY 10022

	Email:	 	  

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	T. Rowe Price Health Sciences Fund, Inc.
	TD Mutual Funds - TD Health Sciences Fund
	VALIC Company I - Health Sciences Fund
	T. Rowe Price Health Sciences Portfolio
	John Hancock Variable Insurance Trust - Health Sciences Trust
	John Hancock Funds II - Health Sciences Fund
	    Each account, severally and not jointly
	
	By: T. Rose Price Associates, Inc., Investment Adviseror Subadviser, as applicable
		
	By:	 	 /s/ Ziad Bakri

	Name:	 	 Ziad Bakri

	Title:	 	 Vice President

	
	T. Rowe Price New Horizons Fund, Inc.
	T. Rowe Price New Horizons Trust
	T. Rowe Price U.S. Equities Trust
	New York City Deferred Compensation Plan
	    Each account, severally and not jointly
	
	By: T. Rose Price Associates, Inc., Investment Adviser
		
	By:	 	 /s/ Ziad Bakri

	Name:	 	 Ziad Bakri

	Title:	 	 Vice President

	
	Address:
	T. Rowe Price Associates, Inc.
	100 E. Pratt Street
	Baltimore, MD 21202
	Email: #####@troweprice.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	PURCHASERS:
	
	Perceptive Life Science Master Fund Ltd.
		
	By:	 	 /s/ James H. Mannix

	Name:	 	 James H. Mannix

	Title:	 	 C.O.O.

 
			
		
	Address:	 	 Perceptive Advisors LLC

	 51 Astor Place, 10th Floor

	 New York, NY 10003

	 Email: ####@perceptivelife.com

  
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 EXHIBIT A 

SCHEDULE OF PURCHASERS 
  

									
	 Name and Address
	  	Number of
Shares	 	  	Aggregate
Purchase Price of
Shares	 
	 The Northern Trust Company, as custodian for Future Fund Investment Company No.4 Pty Ltd

Level 47, 80 Collins Street, Melbourne, Victoria 3000 Australia
	  	 	3,436,426	  	  	$	29,999,998.98	  
			
	 New Enterprise Associates 12, Limited Partnership

c/o New Enterprise Associates
 1954 Greenspring Drive, Suite
600
 Timonium, MD 21093
 Email: LCitron@NEA.com
	  	 	763,650	  	  	$	6,666,664.50	  
			
	 NEA 15 Opportunity Fund, L.P.
 c/o New
Enterprise Associates
 1954 Greenspring Drive, Suite 600

Timonium, MD 21093
 Email: LCitron@NEA.com
	  	 	763,650	  	  	$	6,666,664.50	  
			
	 New Enterprise Associates 15, L.P.
 c/o New
Enterprise Associates
 1954 Greenspring Drive, Suite 600

Timonium, MD 21093
 Email: LCitron@NEA.com
	  	 	763,651	  	  	$	6,666,673.23	  
			
	 EcoR1 Capital Fund Qualified, LP
 409 Illinois
Street
 San Francisco, CA 94158
 Email:
oleg@ecor1cap.com
	  	 	927,377	  	  	$	8,096,001.21	  
			
	 EcoR1 Capital Fund, LP
 409 Illinois Street

San Francisco, CA 94158
 Email: oleg@ecor1cap.com
	  	 	332,646	  	  	$	2,903,999.58	  
			
	 Quadrille Ardelyx, LLC
 c/o Quadrille
Capital
 16 Place de la Madeleine
 75008 Paris, France

Email: hp@quadrillecapital.com
 With copy to:
dshu@quadrillecapital.com
	  	 	801,833	  	  	$	7,000,002.09	  
			
	 Cormorant Global Healthcare Master Fund, LP
 200
Clarendon Street, 52nd Floor
 Boston, MA 02116
 Email:
chen@cormorant-asset.com
	  	 	475,659	  	  	$	4,152,503.07	  
			
	 CRMA SPV, L.P.

PO Box 309

Ugland House

Grand Cayman

KY1-1104 Cayman Islands

Email: chen@cormorant-asset.com
	  	 	97,079	  	  	$	847,499.67	  

									
	 Name and Address
	  	Number of
Shares	 	  	Aggregate
Purchase Price of
Shares	 
	 Rock Springs Capital Master Fund LP
 650 S.
Exeter Street, Ste 1070
 Baltimore, MD 21202
 Email:
jill@rockspringcapital.com
	  	 	687,285	  	  	$	5,999,998.05	  
			
	 RA Capital Healthcare Fund, L.P.
 20 Park Plaza,
Suite 1200
 Boston, MA 02116
	  	 	935,510	  	  	$	8,167,002.30	  
			
	 Blackwell Partners LLC - Series A
 DUMAC,
Inc.
 280 S. Mangum Street, Suite 210
 Durham, NC 27701

Email: Blackwell@dumac.edu
	  	 	209,965	  	  	$	1,832,994.45	  
			
	 Deerfield Special Situations Fund, L.P.
 780
Third Avenue, 37th Floor
 New York, NY 10017
 Email:
dclark@deerfield.com
	  	 	343,643	  	  	$	3,000,003.39	  
			
	 DAFNA LifeScience LP
 DAFNA Capital Management
LLC
 10990 Wilshire Boulevard, Suite 1400
 Los Angeles, CA
90024
 Email: nfischel@DAFNACapital.com
	  	 	137,457	  	  	$	1,199,999.61	  
			
	 DAFNA LifeScience Select LP
 DAFNA Capital
Management LLC
 10990 Wilshire Boulevard, Suite 1400
 Los
Angeles, CA 90024
 Email: nfischel@DAFNACapital.com
	  	 	91,638	  	  	$	799,999.74	  
			
	 First BioMed, L.P.
 399 Park Avenue

New York, NY 10022
	  	 	408,300	  	  	$	3,564,459.00	  
			
	 First Health, L.P.
 399 Park Avenue

New York, NY 10022
	  	 	311,828	  	  	$	2,722,258.44	  
			
	 First BioMed Portfolio, L.P.
 399 Park
Avenue
 New York, NY 10022
	  	 	137,600	  	  	$	1,201,248.00	  
			
	 First Health Limited
 399 Park Avenue

New York, NY 10022
	  	 	111,200	  	  	$	970,776.00	  
			
	 First Health Associates, L.P.
 399 Park
Avenue
 New York, NY 10022
	  	 	62,000	  	  	$	541,260.00	  

  
 2 

									
	 Name and Address
	  	Number of
Shares	 	  	Aggregate
Purchase Price of
Shares	 
	 T. Rowe Price Health Sciences Fund, Inc.
 T.
Rowe Price Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD
21202
 Email: Andrew_baek@troweprice.com
	  	 	125,026	  	  	$	1,091,476.98	  
			
	 TD Mutual Funds - TD Health Sciences Fund
 T.
Rowe Price Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD
21202
 Email: Andrew_baek@troweprice.com
	  	 	6,808	  	  	$	59,433.84	  
			
	 VALIC Company I - Health Sciences Fund
 T. Rowe
Price Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD
21202
 Email: Andrew_baek@troweprice.com
	  	 	8,372	  	  	$	73,087.56	  
			
	 T. Rowe Price Health Sciences Portfolio
 T. Rowe
Price Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD
21202
 Email: Andrew_baek@troweprice.com
	  	 	6,900	  	  	$	60,237.00	  
			
	 John Hancock Variable Insurance Trust - Health Sciences Trust

T. Rowe Price Associates, Inc.
 100 E. Pratt Street

Baltimore, MD 21202
 Email: Andrew_baek@troweprice.com
	  	 	3,128	  	  	$	27,307.44	  
			
	 John Hancock Funds II - Health Sciences Fund
 T.
Rowe Price Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD
21202
 Email: Andrew_baek@troweprice.com
	  	 	2,300	  	  	$	20,079.00	  
			
	 T. Rowe Price New Horizons Fund, Inc.
 T. Rowe
Price Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD
21202
 Email: Andrew_baek@troweprice.com
	  	 	169,922	  	  	$	1,483,419.06	  
			
	 T. Rowe Price New Horizons Trust
 T. Rowe Price
Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD 21202

Email: Andrew_baek@troweprice.com
	  	 	15,180	  	  	$	132,521.40	  

  
 3 

									
	 Name and Address
	  	Number of
Shares	 	  	Aggregate
Purchase Price of
Shares	 
	 T. Rowe Price U.S. Equities Trust
 T. Rowe Price
Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD 21202

Email: Andrew_baek@troweprice.com
	  	 	488	  	  	$	4,260.24	  
			
	 New York City Deferred Compensation Plan
 T.
Rowe Price Associates, Inc.
 100 E. Pratt Street
 Baltimore, MD
21202
 Email: Andrew_baek@troweprice.com
	  	 	5,519	  	  	$	48,180.87	  
			
	 Perceptive Life Science Master Fund Ltd.
 51
Astor Place, 10th Floor
 New York, NY 10003
	  	 	458,190	  	  	$	3,999,998.70	  
		  	  
	  
	 	  	  
	  
	 
	TOTAL	  	 	12,600,230	  	  	$	110,000,007.90	  
		  	  
	  
	 	  	  
	  
	 

  
 4 

 APPENDIX I 

FORM OF PURCHASER QUESTIONNAIRE 

  
 5 

 PURCHASER QUESTIONNAIRE 

To: Ardelyx, Inc. 
 This Purchaser Questionnaire
(“Questionnaire”) must be completed by each potential investor in connection with the offer and sale of the shares of the common stock, par value $0.0001 per share (the “Securities”), of Ardelyx, Inc., a Delaware
corporation (the “Corporation”). The Securities are being offered and sold by the Corporation without registration under the Securities Act of 1933, as amended (the “Securities Act”), and the securities laws
of certain states, in reliance on the exemptions contained in Section 4(a)(2) of the Securities Act and on Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The Corporation must determine that a
potential investor meets certain suitability requirements before offering or selling the Securities to such investor. The purpose of this Questionnaire is to assure the Corporation that each investor will meet the applicable suitability
requirements. The information supplied by you will be used in determining whether you meet such criteria, and reliance upon the private offering exemptions from registration is based in part on the information herein supplied. 

This Questionnaire does not constitute an offer to sell or a solicitation of an offer to buy any security. By signing this Questionnaire, you will be
authorizing the Corporation to provide a completed copy of this Questionnaire to such parties as the Corporation deems appropriate in order to ensure that the offer and sale of the Securities will not result in a violation of the Securities Act or
the securities laws of any state and that you otherwise satisfy the suitability standards applicable to purchasers of the Securities. All potential investors must answer all applicable questions and complete, date and sign this Questionnaire. Please
print or type your responses and attach additional sheets of paper if necessary to complete your answers to any item. 
 PART A. BACKGROUND
INFORMATION 
 Name of Beneficial Owner of the Securities: 
  

													
	Business Address:    	 	 

													
	
	(Number and Street)
							
	City:	 	
                     
                                    
	  	State:	 	
                     

	  	Zip Code:	 	
                     
            
	 	

													
							
	Telephone Number:	 	
                     
                                         
                   
	 		 		 		 		 	
	
	If a corporation, partnership, limited liability company, trust or other entity:

							
				
	Type of entity:	 	  
	    		  	

							
				
	State of formation:	 	  
	    	Approximate Date of formation:	 	  

Were you formed for the purpose of investing in the securities being offered?
    Yes   ̈             No   ̈ 

If an individual: 
  

			
	Residence Address:	 	                                     
                                         
                                         
                     
		 	(Number and Street)                    

 

											
	City:	 	                                    	  		 	State:                     	  	Zip Code:                     
			
	Telephone Number:
                                        
	  		  	
						
	Age:	 	                                    	  		 	Citizenship:                     	  	Where registered to vote:	  	            

  
 6 

 Set forth in the space provided below the state(s), if any, in the United States in which you maintained your
residence during the past two years and the dates during which you resided in each state: 
 Are you a director or executive officer of the Corporation?
    Yes   ̈             No   ̈ 

Social Security or Taxpayer Identification No.:
                                         
        
 PART B. ACCREDITED INVESTOR QUESTIONNAIRE 

In order for the Corporation to offer and sell the Securities in conformance with state and federal securities laws, the following information
must be obtained regarding your investor status. Please initial each category applicable to you as a purchaser of Securities of the Corporation. 
  

			
	 ̈ (1)	 	A bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary
capacity;
		
	 ̈ (2)	 	A broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);
		
	 ̈ (3)	 	An insurance company as defined in Section 2(a)(13) of the Securities Act;
		
	 ̈ (4)	 	An investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that act;
		
	 ̈ (5)	 	A Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;
		
	 ̈ (6)	 	A plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of
$5,000,000;
		
	 ̈ (7)	 	An employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either a bank, savings
and loan association, insurance company or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited
investors;
		
	 ̈ (8)	 	A private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
		
	 ̈ (9)	 	An organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the Securities, with total
assets in excess of $5,000,000;
		
	 ̈ (10)	 	A trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated person who has such knowledge and experience in financial and
business matters that such person is capable of evaluating the merits and risks of investing in the Corporation;

  
 7 

			
	 ̈ (11)	 	A natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000 (exclusive of the value of that person’s primary residence);
		
	 ̈ (12)	 	A natural person who had an individual income in excess of $200,000 in each of the two most recent years, or joint income with that person’s spouse in excess of $300,000, in each of those years, and has a reasonable
expectation of reaching the same income level in the current year;
		
	 ̈ (13)	 	An executive officer or director of the Corporation;
		
	 ̈ (14)	 	An entity in which all of the equity owners qualify under any of the above subparagraphs. If the undersigned belongs to this investor category only, list the equity owners of the undersigned, and the investor category which each
such equity owner satisfies.

 PART C. BAD ACTOR QUESTIONNAIRE 
  

	1.	During the past ten years, have you been convicted of any felony or misdemeanor that is related to any securities matter? 

  

	 	Yes	 ̈ (If yes, please continue to Question 1.a) 

  

	 	No	 ̈ (If no, please continue to Question 2) 

  

	 	a)	If your answer to Question 1 was “yes”, was the conviction related to: (i) the purchase or sale of any security; (ii) the making of any false filing with the Securities and Exchange Commission (the
“SEC”); or (iii) the conduct of an underwriter, broker, dealer, municipal securities dealer, investment adviser or paid solicitor of purchasers of securities? 

Yes   ̈            
No   ̈ 
  

	2.	Are you subject to any court injunction or restraining order entered during the past five years that is related to any securities matter? 

 

	 	Yes	 ̈ (If yes, please continue to Question 2.a) 

  

	 	No	 ̈ (If no, please continue to Question 3) 

  

	 	a)	If your answer to Question 2 was “yes”, does the court injunction or restraining order currently restrain or enjoin you from engaging or continuing to engage in any conduct or practice related to: (i) the
purchase or sale of any security; (ii) the making of any false filing with the SEC; or (iii) the conduct of an underwriter, broker, dealer, municipal securities dealer, investment adviser or paid solicitor of purchasers of securities?

Yes   ̈            
No   ̈ 

  
 8 

	3.	Are you subject to any final order1 of any governmental commission, authority, agency or officer2(2) related
to any securities, insurance or banking matter? 

  

	 	Yes	 ̈ (If yes, please continue to Question 3.a) 

  

	 	No	 ̈ (If no, please continue to Question 4) 

  

	 	a)	If your answer to Question 3 was “yes”: 

  

	 	i)	Does the order currently bar you from: (i) associating with an entity regulated by such commission, authority, agency or officer; (ii) engaging in the business of securities, insurance or banking; or (iii)
engaging in savings association or credit union activities? 

Yes   ̈            
No   ̈ 
  

	 	ii)	Was the order (i) entered within the past ten years and (ii) based on a violation of any law or regulation that prohibits fraudulent, manipulative or deceptive conduct? 

Yes   ̈            
No   ̈ 
  

	4.	Are you subject to any SEC disciplinary order?3(3) 

  

	 	Yes	 ̈ (If yes, please continue to Question 4.a) 

  

	 	No	 ̈ (If no, please continue to Question 5) 

  

	 	a)	If your answer to Question 4 was “yes”, does the order currently: (i) suspend or revoke your registration as a broker, dealer, municipal securities dealer or investment adviser; (ii) place limitations on your
activities, functions or operations; or (iii) bar you from being associated with any particular entity or class of entities or from participating in the offering of any penny stock? 

 

	5.	Are you subject to any SEC cease and desist order entered within the past five years? 

  

	 	Yes	 ̈ (If yes, please continue to Question 5.a) 

  

	 	No	 ̈ (If no, please continue to Question 6) 

  

	 	a)	If your answer to Question 5 was “yes”, does the order currently require you to cease and desist from committing or causing a violation or future violation of (i) any knowledge-based anti-fraud provision
of the U.S. federal securities laws4 or (ii) Section 5 of the Securities Act? 

Yes   ̈            
No   ̈ 
  

 

	1 	A “final order” is defined under Rule 501(g) as a written directive or declaratory statement issued by a federal or state agency described in Rule 506(d)(1)(iii) under applicable statutory authority that
provides for notice and an opportunity for a hearing, and that constitutes a final disposition or action by such federal or state agency. 

	2 	You may limit your response to final orders of: (i) state securities commissions (or state agencies/officers that perform a similar function); (ii) state authorities that supervise or examine banks, savings associations
or credit unions; (iii) state insurance commissions (or state agencies/officers that perform a similar function); (iv) federal banking agencies; (v) the U.S. Commodity Futures Trading Commission; or (vi) the U.S. National Credit Union
Administration. 

	3 	You may limit your response to disciplinary orders issued pursuant to Sections 15(b) or 15B(c) of the Exchange Act or Section 203(e) or (f) of the Investment Advisers Act of 1940 (the “Advisers Act”).

	4 	Including (but not limited to) Section 17(a)(1) of the Securities Act, Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, Section 15(c)(1) of the Exchange Act, and Section 206(1) of the Advisers Act or any
other rule or regulation thereunder. 

  
 9 

	6.	Have you been suspended or expelled from membership in, or suspended or barred from association with a member of, a registered national securities exchange or a registered national or affiliated securities
association? 

  

	 	Yes     ̈	(If yes, please describe the basis of any such suspension or expulsion and any related details in the space provided under Question 10 below)5 

 

	 	No      ̈	(If no, please continue to Question 7) 

  

	7.	Have you registered a securities offering with the SEC, made an offering under Regulation A or been named as an underwriter in any registration statement or Regulation A offering statement filed with the SEC?

  

	 	Yes     ̈	(If yes, please continue to Question 7.a) 

  

	 	No      ̈	(If no, please continue to Question 8) 

  

	 	a)	If your answer to Question 7 was “yes”: 

  

	 	i)	During the past five years, was any such registration statement or Regulation A offering statement the subject of a refusal order, stop order or order suspending the Regulation A exemption? 

Yes   ̈            
No   ̈ 
  

	 	ii)	Is any such registration statement or Regulation A offering statement currently the subject of an investigation or proceeding to determine whether a stop order or suspension order should be issued? 

Yes   ̈            
No   ̈ 
  

	8.	Are you subject to a U.S. Postal Service false representation order entered within the past five years? 

  

	 	Yes   ̈                    	No   ̈ 

  

	9.	Are you currently subject to a temporary restraining order or preliminary injunction with respect to conduct alleged by the U.S. Postal Service to constitute a scheme or device for obtaining money or property through
the mail by means of false representations? 

  

	 	Yes   ̈                    	No   ̈ 

  

	10.	In the space provided below, describe any facts or circumstances that caused you to answer “yes” to any Question (indicating the corresponding Question number). Attach additional pages if necessary.

  
  

	5 	In providing additional information, please explain whether or not the suspension or expulsion resulted from “any act or omission to act constituting conduct inconsistent with just and equitable principles of
trade.” 

  
 10 

	A.	FOR EXECUTION BY AN INDIVIDUAL: 

  

									
			
		 	By:	 	 
			
		 	Print Name:	 	 

	
	
                      
  

	 Date

  

	B.	FOR EXECUTION BY AN ENTITY: 

  

			
	Entity Name:	 	 

 
									
			
		 	By:	 	 
			
		 	Print Name:	 	 
			
		 	Title:	 	 

	
	
                      
  

	 Date

  

	C.	ADDITIONAL SIGNATURES (if required by partnership, corporation or trust document): 

  

									
	Entity Name:	 	 

 
									
			
		 	By:	 	 
			
		 	Print Name:	 	 
			
		 	Title:	 	 

	
	
                      
  

	 Date

 
			
	Entity Name:	 	 

 
									
			
		 	By:	 	 
			
		 	Print Name:	 	 
			
		 	Title:	 	 

	
	
                      
  

	 Date

  
 11 

 APPENDIX II 

FORM OF SELLING STOCKHOLDER QUESTIONNAIRE 
  

	
	                                      
                                  
	Name of Selling Stockholder (please print)

 ARDELYX, INC. 

QUESTIONNAIRE FOR SELLING STOCKHOLDERS 

IMPORTANT: IMMEDIATE ATTENTION REQUIRED 

This Questionnaire is being furnished to all persons or entities (the “Purchasers”) electing to purchase shares of Common
Stock (“Common Stock”) of Ardelyx, Inc. (the “Company”) pursuant to the Securities Purchase Agreement by and among the Company and the Purchasers (the “Purchase Agreement”) to which this Questionnaire is an Appendix.
This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-3 (the “Registration Statement”) being prepared by the Company for filing with the United States Securities and
Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by and among the Company and the Purchasers (the “Registration Rights Agreement”) in connection with the Purchase Agreement. The
Company must receive a completed Questionnaire from each Purchaser in order to include such Purchaser’s shares of Common Stock in the Registration Statement. 

The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important part of the
registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information. Accordingly,
Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. 

PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where appropriate. Please
complete, sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. 

Latham & Watkins 
 140
Scott Drive 
 Menlo Park, CA 94025 

Attn: Alexander White 
 Fax:
(650) 463-2600 
 alexander.white@lw.com 

Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to inform
us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact Alexander White at (650) 470-4964 or
alexander.white@lw.com. 

  
 12 

 PART I - STOCK OWNERSHIP 

 

	 	Item 1.	Beneficial Ownership. 

 a. Deemed Beneficial Ownership. Please state the amount of
securities of the Company you own on the date you complete this Questionnaire. (If none, please so state in each case.) 
  

					
	 Amount Beneficially
Owned1
	  	Number of Shares of
Common Stock Owned	 
	 Please state the number of shares owned by you or by family members, trusts and other organizations with which you have
a relationship, and any other shares of which you may be deemed to be the “beneficial owner“1:
	  			
		
	 Total Shares:
	  	  
	  
	 
		
	 Of such shares:
	  			
		
	 Shares as to which you have sole voting power:
	  	  
	  
	 
		
	 Shares as to which you have shared voting power:
	  	  
	  
	 
		
	 Shares as to which you have sole investment power:
	  	  
	  
	 
		
	 Shares as to which you have shared investment power:
	  	  
	  
	 
		
	 Shares which you will have a right to acquire before 60 days after the date you complete this questionnaire through the
exercise of options, warrants or otherwise:
	  	  
	  
	 

  
 13 

 Do you have any present plans to exercise options or otherwise acquire, dispose of or to transfer
shares of Common Stock of the Company between the date you complete this Questionnaire and the date which is 60 days after the date in which the Registration Statement is filed? 

Answer: 
 If so, please
describe. 
 b. Pledged Securities. If any of such securities have been pledged or otherwise deposited as collateral or are the
subject matter of any voting trust or other similar agreement or of any contract providing for the sale or other disposition of such securities, please give the details thereof. 

Answer: 
 c. Disclaimer of
Beneficial Ownership. Do you wish to disclaim beneficial ownership1 of any of the shares reported in response to Item 1(a)? 

Answer: 
 If the answer is
“Yes”, please furnish the following information with respect to the person or persons who should be shown as the beneficial owner(s)1 of the shares in question. 

 

									
	 Name and Address of

Actual Beneficial Owner
	  	Relationship of
Such Person To You	 	  	Number of Shares
Beneficially Owned	 
		  				  			
		  				  			
		  				  			

 d. Shared Voting or Investment Power over Securities. Will any person be deemed to have beneficial
ownership over any of the Securities purchased by you pursuant to the Purchase Agreement? 
 Answer: 

If the answer is “Yes”, please furnish the following information with respect to the person or persons who should be shown as the
beneficial owner(s)1 of the Securities in question. 
  

									
	 Name and Address of

Beneficial Owner
	  	Relationship of
Such Person To You	 	  	Number of Shares
Beneficially Owned	 
		  				  			
		  				  			
		  				  			

  
 14 

 Item 2. Major Shareholders. Please state below the names of persons or groups
known by you to own beneficially1 more than 5% of the Company’s Common Stock. 

Answer: 
 Item 3.
Change of Control. Do you know of any contractual arrangements, including any pledge of securities of the Company, the operation of which may at a subsequent date result in a change of control of the Company? 

Answer: 
 Item 4.
Relationship with the Company. Please state the nature of any position, office or other material relationship you have, or have had within the past three years, with the Company or its affiliates. 

 

					
	 Name
	  	Nature of
Relationship	 
		  			
		  			
		  			

 Item 5. Broker-Dealer Status. Is the Purchaser a broker-dealer registered pursuant to
Section 15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)? 

 ̈ Yes. 

 ̈ No. 

If so, please answer the remaining questions under this Item 5. 

Note that the Company will be required to identify any registered broker-dealer as an underwriter in the Registration Statement and related
prospectus. 
 a. If the Purchaser is a registered broker-dealer, please indicate whether the Purchaser purchased its Common Stock for
investment or acquired them as transaction-based compensation for investment banking or similar services. 
 Answer: 

Note that if the Purchaser is a registered broker-dealer and received its Common Stock other than as transaction-based compensation, the
Company is required to identify the Purchaser as an underwriter in the Registration Statement and related prospectus. 

  
 15 

 b. Is the Purchaser an affiliate of a registered broker-dealer? For purposes of this Question, an
“affiliate” of a specified person or entity means a person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the person or entity specified. 

 ̈ Yes. 

 ̈ No. 

If so, please answer questions (i)-(iii) below under this Item 5(b). 

i. Please describe the affiliation between the Purchaser and any registered broker-dealers: 

ii. If the Common Stock was received by the Purchaser other than in the ordinary course of business, please describe the
circumstances: 
 iii. If the Purchaser, at the time of its receipt of Common Stock, has had any agreements or
understandings, directly or indirectly, with any person to distribute the Common Stock, please describe such agreements or understandings: 

Note that if the Purchaser is an affiliate of a broker-dealer and did not receive its Common Stock in the
ordinary course of business or at the time of receipt had any agreements or understandings, directly or indirectly, to distribute the securities, the Company must identify the Purchaser as an underwriter in the Registration Statement and related
prospectus. 
 Item 6. Nature of Beneficial Holding. The purpose of this question is to identify the ultimate natural
person(s) or publicly held entity that exercise(s) sole or shared voting or dispositive power over the Registrable Securities (as defined in the Registration Rights Agreement). 

a. Is the Purchaser a natural person? 

 ̈ Yes. 

 ̈ No. 

  
 16 

 b. Is the Purchaser required to file, or is it a wholly owned subsidiary of a company that is
required to file, periodic and other reports (for example, Form 10-K, 10-Q, 8-K) with the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act? 

 ̈ Yes. 

 ̈ No. 

c. Is the Purchaser an investment company, or a subsidiary of an investment company, registered under the Investment Company Act of 1940, as
amended? 
  ̈ Yes. 

 ̈ No. 

If a subsidiary, please identify the publicly held parent entity: 

d. If you answered “no” to questions (a), (b) and (c) above, please identify the controlling person(s) of the Purchaser
(the “Controlling Entity”). If the Controlling Entity is not a natural person or a publicly held entity, please identify each controlling person(s) of such Controlling Entity. This process should be repeated until you reach natural persons
or a publicly held entity that exercises sole or shared voting or dispositive power over the Registrable Securities: 
 ***PLEASE NOTE
THAT THE SEC REQUIRES THAT THESE NATURAL PERSONS BE NAMED IN THE PROSPECTUS*** 
 PART II - CERTAIN TRANSACTIONS 

Item 7. Transactions with the Company. If you, any of your
associates2, or any member of your immediate family3 had or will have any direct or indirect material interest in any transactions4 or series of transactions to which the Company or any of its subsidiaries was a party at any time since January 1, 2015, or in any currently proposed transactions or series of transactions in
which the Company or any of its subsidiaries will be a party, in which the amount involved exceeds $120,000, please specify (a) the names of the parties to the transaction(s) and their relationship to you, (b) the nature of the interest in
the transaction, (c) the amount involved in the transaction, and (d) the amount of the interest in the transaction. If the answer is “none”, please so state. 

  
 17 

 Answer: 

Item 8. Third Party Payments. Please describe any compensation paid to you by a third party pursuant to any arrangement
between the Company and any such third party. 
 Answer: 

PART III – PLAN OF DISTRIBUTION 

The selling stockholders and any of their pledgees, donees, transferees, assignees or other successors-in-interest may, from time to time,
sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions
may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The selling stockholders may use one or more of the
following methods when disposing of the shares or interests therein: 
  

	 	•	 	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	 	•	 	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; 

 

	 	•	 	through brokers, dealers or underwriters that may act solely as agents; 

  

	 	•	 	purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	 	•	 	an exchange distribution in accordance with the rules of the applicable exchange; 

  

	 	•	 	privately negotiated transactions; 

  

	 	•	 	through the writing or settlement of options or other hedging transactions entered into after the effective date of the registration statement of which this prospectus is a part, whether through an options exchange or
otherwise; 

  

	 	•	 	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	 	•	 	a combination of any such methods of disposition; and 

  

	 	•	 	any other method permitted pursuant to applicable law. 

  
 18 

 The selling stockholders may also sell shares under Rule 144 or Rule 904 under the Securities Act
of 1933, as amended, or Securities Act, if available, or Section 4(a)(1) under the Securities Act, rather than under this prospectus. 

Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to
exceed what is customary in the types of transactions involved. 
 The selling stockholders may, from time to time, pledge or grant a
security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell shares of common stock from time to time under this
prospectus, or under a supplement or amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest
as selling stockholders under this prospectus. 
 Upon being notified in writing by a selling stockholder that any material arrangement has
been entered into with a broker-dealer for the sale of common stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, we will file a supplement to this prospectus, if
required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares involved, (iii) the price at which such shares
of common stock were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or
incorporated by reference in this prospectus, and (vi) other facts material to the transaction. In addition, upon being notified in writing by a selling stockholder that a donee or pledge intends to sell more than 500 shares of common stock, we
will file a supplement to this prospectus if then required in accordance with applicable securities law. 
 The selling stockholders also
may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 

In connection with the sale of the shares of common stock or interests in shares of common stock, the selling stockholders may enter into
hedging transactions after the effective date of the registration statement of which this prospectus is a part with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging
the positions they assume. The selling stockholders may also sell shares of common stock short after the effective date of the registration statement of which this prospectus is a part and deliver these securities to close out their short positions,
or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions after the effective date of the registration statement of which this prospectus is
a part with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial 

  
 19 

 
institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such
transaction). 
 The selling stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be
“underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to
be underwriting commissions or discounts under the Securities Act. The maximum commission or discount to be received by any member of the Financial Industry Regulatory Authority (FINRA) or independent broker-dealer will not be greater than 8% of the
initial gross proceeds from the sale of any security being sold. 
 We have advised the selling stockholders that they are required to
comply with Regulation M promulgated under the Securities Exchange Act of 1934, as amended, during such time as they may be engaged in a distribution of the shares. The foregoing may affect the marketability of the common stock. 

The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly
or through agents. We will not receive any of the proceeds from this offering. 
 We are required to pay all fees and expenses incident to
the registration of the shares. We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act or otherwise. 

We have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until
the earlier of (a) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or (b) the date on which the shares of common stock covered by this prospectus
may be sold or transferred by non-affiliates without any volume limitations or pursuant to Rule 144 of the Securities Act. 

*        *        * 

The undersigned has reviewed the Plan of Distribution set forth above and does not have a present intention of effecting a sale in a manner
not described therein. 
  

					
	                    	  	Agree                                  
             Disagree
		  	(If left blank, response will be deemed to be “Agree”.)

 The undersigned hereby represents that the undersigned understands, pursuant to Interpretation A.65 in the
Securities and Exchange Commission, Division of Corporation Finance, Manual of Publicly Available Telephone Interpretations dated July 1997, a copy of 

  
 20 

 
which is attached hereto as Exhibit 1, that the undersigned may not make any short sale of the Common Stock prior to the effectiveness of the Registration Statement, and further covenants to the
Company that the undersigned will not engage in any short sales of such stock to be registered under the Registration Statement prior to its effectiveness. 

  
 21 

 SIGNATURE 

The undersigned understands that the Company anticipates filing the Registration Statement within the time frame set forth in the Registration
Rights Agreement. If at any time any of the information set forth in my responses to this Questionnaire has materially changed due to passage of time (other than due to the receipt of the Common Stock set forth opposite the undersigned’s name
in the Schedule of Purchasers in the Purchase Agreement), or any development occurs which requires a change in any of my answers, or has for any other reason become incorrect, the undersigned agrees to furnish as soon as practicable to the
individual to whom a copy of this Questionnaire is to be sent, as indicated and at the address shown on the first page hereof, any necessary or appropriate correcting information. Otherwise, the Company is to understand that the above information
continues to be, to the best of my knowledge, information and belief, complete and correct. 
 Upon any sale of Common Stock pursuant to the
Registration Statement, the undersigned hereby agrees to deliver to the Company and the Company’s transfer agent the Certificate of Subsequent Sale set forth in Exhibit I hereto. 

The undersigned understands that the information that the undersigned is furnishing to the Company herein will be used by the Company in the
preparation of the Registration Statement. 
  

					
		 	Name of Purchaser:	 	  

					
			
	Date:                     , 2016	 	Signature:	 	  

					
			
		 	Print Name:	 	  

					
			
		 	Title (if applicable):	 	  

		 	Address:	 	

					
			
		 		 	  
 Street

			
		 		 	  
 Street

			
		 		 	  
 City
                                        State
                                        Zip 
Code

			
		 		 	  
 Telephone Number

			
		 		 	  
 Email Address

  
 22 

 FOOTNOTES 
  

	1.	Beneficial Ownership. You are the beneficial owner of a security, as defined in Rule 13d-3 under the Securities Exchange Act of 1934 (the “Exchange Act”), if you, directly or indirectly, through
any contract, arrangement, understanding, relationship or otherwise have or share: (1) voting power, which includes the power to vote, or to direct the voting of, such security, and/or (2) investment power, which includes the power to
dispose, or to direct the disposition of, such security. You are also the beneficial owner of a security if you, directly or indirectly, create or use a trust, proxy, power of attorney, pooling arrangement or any other contract, arrangement or
device with the purpose or effect of divesting yourself of beneficial ownership of a security or preventing the vesting of such beneficial ownership. 

You are deemed to be the beneficial owner of a security if you have the right to acquire beneficial ownership of such security at any time
within 60 days including, but not limited to, any right to acquire such security (a) through the exercise of any option, warrant or right, (b) through the conversion of a security, or (c) pursuant to the automatic termination
of, or the power to revoke a trust, discretionary account, or similar arrangement. 
 Ordinarily, shares held in the name of your spouse or
minor child should be considered as beneficially owned by you absent special circumstances to indicate that you do not have, as a practical matter, voting power or investment power over such shares. Similarly, absent countervailing facts, securities
held in the name of relatives who share your home are to be reported as being beneficially owned by you. In addition, securities held for your benefit in the name of others, such as nominees, trustees and other fiduciaries, securities held by a
partnership of which you are a partner, and securities held by a corporation controlled by you should be regarded as beneficially owned by you. 

This definition of beneficial ownership is very broad; therefore, even though you may not actually have or share voting or investment power
with respect to securities owned by persons in your family or living in your home, you should include such shares in your beneficial ownership disclosure and may then disclaim beneficial ownership of such securities. 

 

	2.	Associate. The term “associate”, as defined in Rule 14a-1 under the Exchange Act, means (a) any corporation or organization (other than the Company or any of its majority owned subsidiaries)
of which you are an officer or partner or are, directly or indirectly, the beneficial owner of 10% or more of any class of equity securities, (b) any trust or other estate in which you have a substantial beneficial interest or as to which you
serve as trustee or in a similar capacity, and (c) your spouse, or any relative of yours or relative of your spouse living in your home or who is a director or officer of the Company or of any subsidiary. The term “relative of yours”
as used in this Questionnaire refers to any relative or spouse of yours, or any relative of such spouse, who has the same home as you or who is a director or officer of any subsidiary of the Company. 

Please identify your associate referred to in your answer and indicate your relationship. 

  
 23 

	3.	Immediate Family. The members of your “immediate family” are deemed to include the following: your spouse; your parents; your children; your siblings; your mother-in-law or father-in-law; your sons- and
daughters-in-law; and your brothers- and sisters-in-law. 

  

	4.	Transactions. The term “transaction” is to be understood in its broadest sense, and includes the direct or indirect receipt of anything of value. Please note that indirect as well as direct material
interests in transactions are to be disclosed. Transactions in which you would have a direct interest would include your purchasing or leasing anything (stock in a business acquired by the Company, office space, plants, Company apartments,
computers, raw materials, finished goods, etc.) from or selling or leasing anything to, or borrowing or lending cash or other property from or to, the Company, or any subsidiary. 

  
 24 

 Exhibit 1 

Securities Act Sections Compliance and Disclosure Interpretations Section 239.10: “An issuer filed a Form S-3 registration statement
for a secondary offering of common stock which is not yet effective. One of the selling shareholders wanted to do a short sale of common stock “against the box” and cover the short sale with registered shares after the effective date. The
issuer was advised that the short sale could not be made before the registration statement becomes effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of
Section 5 if the shares were effectively sold prior to the effective date.” 

  
 25 

 Exhibit I 

CERTIFICATE OF SUBSEQUENT SALE 
 American
Stock Transfer & Trust Company, LLC 
  

	 	RE:	Sale of Shares of Common Stock of Ardelyx, Inc. (the “Company”) pursuant to the Company’s Prospectus dated             ,
         (the “Prospectus”) 

 Dear Sir/Madam: 

The undersigned hereby certifies, in connection with the sale of shares of Common Stock of the Company included in the table of Selling
Stockholders in the Prospectus, that the undersigned has sold the shares pursuant to the Prospectus and in a manner described under the caption “Plan of Distribution” in the Prospectus and that such sale complies with all securities laws
applicable to the undersigned, including, without limitation, the Prospectus delivery requirements of the Securities Act of 1933, as amended. 
  

			
	Selling Stockholder (the beneficial owner):	 	  

			
		
	Record Holder (e.g., if held in name of nominee):	 	  

			
		
	Book Entry Position or Restricted Stock Certificate No.(s):	 	  

			
		
	Number of Shares Sold:	 	  

			
		
	Date of Sale:	 	  

 In the event that you receive a stock certificate(s) or evidence of a book entry position representing more
shares of Common Stock than have been sold by the undersigned, then you should return to the undersigned a newly issued certificate or book entry position for such excess shares in the name of the Record Holder and BEARING A RESTRICTIVE
LEGEND. Further, you should place a stop transfer on your records with regard to such certificate. Notwithstanding the foregoing, in the event that the undersigned executes and delivers to you and to the Company the certification set forth on
Annex I, upon instructions from the Company, you should return to the undersigned a newly issued certificate or book entry position for such excess shares of Common Stock in the name of the Record Holder without any restrictive legend. In addition,
no subsequent certification will be required to be delivered to you by the undersigned provided that the representations and warranties set forth on Annex I have been delivered to you and continue to be accurate. 

  
 26 

							
		 		 	 Very truly yours,
				
	          Dated:
                                         
                   
	 		 	 By:	 	  

							
		 		 	  Print Name:	 	  

							
		 		 	Title:	 	  

  

	cc:	Ardelyx, Inc. 

 34175 Ardenwood Blvd. 

Suite 200 
 Fremont, CA 94555 

Attn: General Counsel 

  
 27 

 Annex I 

In connection with any excess shares to be returned to the Selling Stockholder upon a sale of shares of Common Stock of Ardelyx, Inc. (the
“Company”) included in the table of Selling Stockholders in the Prospectus, the undersigned hereby certifies to the Company and American Stock Transfer & Trust Company, LLC, that: 

1. In connection with the sale by the undersigned stockholder of any of the shares of Common Stock, the undersigned stockholder will deliver a
copy of the Prospectus included in the Registration Statement to the purchaser directly or through the undersigned stockholder’s broker-dealer in compliance with the requirements of the Securities Act of 1933 and the Securities Exchange Act of
1934. 
 2. Any such sale will be made only in the manner described under “Plan of Distribution” in the Prospectus. 

3. The undersigned stockholder will only sell the shares of Common Stock while the Registration Statement is effective, unless another
exemption from registration is available. 
 4. The Company and its attorneys may rely on this letter to the same extent as if it were
addressed to them. 
 5. The undersigned stockholder agrees to notify you immediately of any development or occurrence which to his, her or
its knowledge would render any of the foregoing representations and agreements inaccurate. 
 All terms not defined herein are as defined in
the Securities Purchase Agreement entered into in July 2016 among the Company and the Purchasers. 
  

							
		 		 	Very truly yours,
				
	          Dated:
                                         
                   
	 		 	By:	 	  

							
		 		 	Print Name:	 	  

							
		 		 	Title:	 	  

  
 28 

 APPENDIX III 

FORM OF REGISTRATION RIGHTS AGREEMENT 

  
 29 

 REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 14, 2016, by and among
Ardelyx, Inc., a Delaware corporation (the “Company”), Future Fund Investment Company No.4 Pty Ltd, a proprietary limited company organized under the laws of Australia (the “FF Beneficial Investor”), The Northern
Trust Company in its capacity as custodian (the “FF Investor”) for the FF Beneficial Investor, and each of the other parties signatory hereto (such other parties and the FF Investor, each a “Purchaser” and together,
the “Purchasers”). 
 The Purchasers and the FF Beneficial Investor shall herein be collectively referred to as the
“Investors” and each as an “Investor.” 
 This Agreement is made pursuant to the Securities Purchase
Agreement, dated as of July 14, 2016, among the Company and the Investors (the “Purchase Agreement”). 
 NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Investors agree as follows: 

1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the
meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the respective meanings set forth in this Section 1: 

“Advice” shall have the meaning set forth in Section 7(d). 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or more
intermediaries, Controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act. 

“Control” (including the terms “controlling”, “controlled by” or “under common control with”)
means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Commission” means the United States Securities and Exchange Commission, or any successor entity or entities, including, if
applicable, the staff of the Commission. 
 “Common Stock” means the common stock, par value $0.0001 per share, of the
Company. 
 “Closing Date” shall have the meaning set forth in the Purchase Agreement. 

“Effectiveness Date” means: (a) with respect to the Initial Registration Statement required to be filed hereunder, the
90th day following the Closing Date (or the 120th day following the Closing Date in the event the Initial Registration Statement is reviewed by
the 

  
 30 

 
Commission), (b) with respect to any additional Registration Statements which may be required pursuant to Section 2, the 90th day
following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required under such Section (or the 120th day following such
date in the event such additional Registration Statement is reviewed by the Commission). If the Effectiveness Date falls on a Saturday, Sunday or other date that the Commission is closed for business, the Effectiveness Date shall be extended to the
next day on which the Commission is open for business. 
 “Effectiveness Period” shall have the meaning set forth in
Section 2(a). 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“FF Beneficial Investor” shall have the meaning set forth in the Preamble to this Agreement. 

“FF Side Letter” means the letter agreement in substantially the form attached as Appendix IV to the Purchase Agreement, to be
entered into by and among the Company, the FF Beneficial Investor and the FF Investor. 
 “Filing Date” means:
(a) with respect to the Initial Registration Statement, the 45th calendar day following the Closing Date, and (b) with respect to any additional Registration Statements that may be
required pursuant to Section 2 hereof, the 45th day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is
required under such Section. 
 “Holder” or “Holders” means the holder or holders, as the case may be,
from time to time of Registrable Securities. 
 “Indemnified Party” shall have the meaning set forth in Section 6(c).

 “Indemnifying Party” shall have the meaning set forth in Section 6(c). 

“Initial Registration Statement” shall mean the initial Registration Statement required to be filed to cover the resale by
the Holders of the Registrable Securities pursuant to Section 2(a). 
 “Investor” shall have the meaning set forth in
the Preamble to this Agreement. 
 “Losses” shall have the meaning set forth in Section 6(a). 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or
partial proceeding, such as a deposition), whether commenced or threatened. 

  
 31 

 “Prospectus” means the prospectus included in a Registration Statement
(including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A or Rule 430B promulgated by the Commission pursuant to
the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the
Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 

“Reduction Securities” shall have the meaning set forth in Section 2(b). 

“Registrable Securities” means (i) the Shares issued pursuant to the Purchase Agreement and (ii) any other shares
of Common Stock issued as (or issuable upon conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, in exchange for or in replacement of the Shares; provided,
however, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so
long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with
such effective Registration Statement, (b) such Registrable Securities have been previously sold or transferred in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions
and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Company’s transfer agent and the affected Holders (assuming that such securities and
any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company), as reasonably determined by the Company, upon
the advice of counsel to the Company. 
 “Registration Statement” means each of the following: (i) an initial
registration statement which is required to register the resale of the Registrable Securities, and (ii) each additional registration statement, if any, contemplated by Section 2, and including, in each case, the Prospectus, amendments and
supplements to each such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement.

 “Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from
time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

  
 32 

 “Rule 424” means Rule 424 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Securities Act” means the Securities Act of 1933, as amended. 

“Shares” shall have the meaning set forth in the Purchase Agreement. 

“Trading Day” means any day on which the Common Stock is traded on the Nasdaq Global Market, or, if the Nasdaq Global Market
is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded. 

“Transaction Documents” shall have the meaning set forth in the Purchase Agreement. 

“Underwritten Offering” means a registration in which Registrable Securities are sold to an underwriter for reoffering to the
public. 
 2. Registration. 

(a) On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all
of the Registrable Securities that are not then registered on an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. The Registration Statement filed hereunder shall be on Form S-3
(except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance herewith) and shall contain (except if otherwise
required pursuant to written comments received from the Commission upon a review of such Registration Statement) the “Plan of Distribution” in substantially the form attached hereto as Annex A (which may be modified to respond to
comments, if any, provided by the Commission). The Company shall use its commercially reasonable efforts to cause a Registration Statement filed under this Agreement to be declared effective under the Securities Act promptly but, in any event, no
later than the Effectiveness Date for such Registration Statement, and shall, subject to Section 7(d) hereof, use its commercially reasonable efforts to keep the Registration Statement continuously effective under the Securities Act until the
earlier of (i) the date that is three years after the Closing Date and (ii) the date on which all securities under such Registration Statement have ceased to be Registrable Securities (the “Effectiveness Period”).
Notwithstanding the foregoing, the Company shall be entitled to suspend the effectiveness of the Registration Statement at any time prior to the expiration of the Effectiveness Period for up to an aggregate of 30 consecutive Trading Days or an
aggregate of 60 Trading Days (which need not be consecutive) in any given 360-day period. It is agreed and understood that the Company shall, from time to time, be obligated to file one or more additional Registration Statements to cover any
Registrable Securities which are not registered for resale pursuant to a pre-existing Registration Statement. 

  
 33 

 (b) Notwithstanding anything contained herein to the contrary, in the event that the Commission
limits the amount of Registrable Securities that may be included and sold by Holders in any Registration Statement, including the Initial Registration Statement, pursuant to Rule 415 or any other basis, the Company may reduce the number of
Registrable Securities included in such Registration Statement on behalf of the Holders in whole or in part (in case of an exclusion as to a portion of such Registrable Securities, such portion shall be allocated pro rata among such Holders in
proportion to the respective numbers of Registrable Securities represented by Shares requested to be registered by each such Holder over the total amount of Registrable Securities represented by Shares) (such Registrable Securities, the
“Reduction Securities”). In such event the Company shall give the Holders prompt notice of the number of such Reduction Securities excluded and the Company will not be liable for any damages under this Agreement in connection with
the exclusion of such Reduction Securities. The Company shall use its commercially reasonable efforts at the first opportunity that is permitted by the Commission to register for resale the Reduction Securities. Such new Registration Statement shall
be on Form S-3 (except if the Company is not then eligible to register for resale the Reduction Securities on Form S-3, in which case such registration shall be on another appropriate form for such purpose) and shall contain (except if
otherwise required pursuant to written comments received from the Commission upon a review of such Registration Statement) the “Plan of Distribution” in substantially the form attached hereto as Annex A (which may be modified to
respond to comments, if any, provided by the Commission). The Company shall use its commercially reasonable efforts to cause each such Registration Statement to be declared effective under the Securities Act as soon as possible but, in any event, no
later than the Effectiveness Date, and shall use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities Act during the entire Effectiveness Period, subject to Section 7(d) hereof.
Notwithstanding the foregoing, the Company shall be entitled to suspend the effectiveness of such Registration Statement at any time prior to the expiration of the Effectiveness Period for an aggregate of no more than 30 consecutive Trading Days or
an aggregate of 60 Trading Days (which need not be consecutive) in any given 360-day period. 
 (c) If: (i) the Initial Registration
Statement is not filed with the Commission on or prior to the Filing Date, (ii) the Initial Registration Statement is not declared effective by the Commission (or otherwise does not become effective) on or prior to the Effectiveness Date or
(iii) after the date it is declared effective by the Commission and except as provided in Section 3(i), (A) such Registration Statement ceases for any reason (including without limitation by reason of a stop order, or the
Company’s failure to update the Registration Statement), to remain continuously effective as to all Registrable Securities included in such Registration Statement or (B) the Holders are not permitted to utilize the Prospectus therein to
resell such Registrable Securities for any reason (other than due to a change in the “Plan of Distribution” or the inaccuracy of any information regarding the Holders) in each case for more than an aggregate of thirty (30) consecutive
Trading Days or sixty (60) Trading Days (which need not be consecutive) in any given 360-day period (other than as a result of a breach of this Agreement by such Holder), or (iv) the Company fails to satisfy the current public information
requirement pursuant to Rule 144(c)(1) as a result of which the Holders who are not affiliates are unable to sell Registrable Securities without restriction under Rule 144 (or any successor thereto), (any such failure or breach in
clauses (i) through (iv) above being referred to as an “Event,” and, for purposes of clauses (i), (ii) or (iv), the date on which such Event occurs, or for purposes of clause (iii), the date on which such thirty
(30) or sixty (60) Trading Day period is exceeded, being 

  
 34 

 
referred to as an “Event Date”), then in addition to any other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly
anniversary of each such Event Date (if the applicable Event shall not have been cured by such date) until the earlier of (1) the applicable Event is cured or (2) the Registrable Securities are eligible for resale pursuant to Rule 144
without manner of sale or volume restrictions or the current public information requirement, the Company shall pay to each Holder an amount in cash, as liquidated damages and not as a penalty (“Liquidated Damages”), equal to one
percent (1%) of the aggregate purchase price paid by such Holder pursuant to the Purchase Agreement for any unregistered Registrable Securities then held by such Holder. The parties agree that (1) notwithstanding anything to the
contrary herein or in the Purchase Agreement, no Liquidated Damages shall be payable with respect to any period after the expiration of the Effectiveness Period (except in respect of an Event described in Section 2(c)(iv) herein), (it
being understood that this sentence shall not relieve the Company of any Liquidated Damages accruing prior to the Effectiveness Deadline) and in no event shall, the aggregate amount of Liquidated Damages (excluding Liquidated Damages payable in
respect of an Event described in Section 2(c)(iv) herein) payable to a Holder exceed, in the aggregate, five percent (5%) of the aggregate purchase price paid by such Holder pursuant to the Purchase Agreement) and (2) in no event
shall the Company be liable in any thirty (30) day period for Liquidated Damages under this Agreement in excess of one percent (1%) of the aggregate purchase price paid by the Holders pursuant to the Purchase Agreement. The Liquidated
Damages pursuant to the terms hereof shall apply on a daily pro-rata basis for any portion of a month prior to the cure of an Event, except in the case of the first Event Date. The Company shall not be liable for Liquidated Damages under this
Agreement as to any Registrable Securities which are not permitted by the Commission to be included in a Registration Statement. In such case, the Liquidated Damages shall be calculated to only apply to the percentage of Registrable Securities
which are permitted to be included in such Registration Statement. The Effectiveness Deadline for a Registration Statement shall be extended without default or Liquidated Damages hereunder in the event that the Company’s failure to obtain the
effectiveness of the Registration Statement on a timely basis results from the failure of a Purchaser to timely provide the Company with information requested by the Company and necessary to complete the Registration Statement in accordance
with the requirements of the Securities Act (in which case the Effectiveness Deadline would be extended with respect to Registrable Securities held by such Purchaser). 

3. Registration Procedures. 

In connection with the Company’s registration obligations hereunder, the Company shall: 

(a) Not less than three Trading Days prior to the filing of a Registration Statement or any related Prospectus or any amendment or supplement
thereto, furnish to the Holders copies of all such documents proposed to be filed (other than those incorporated by reference). Notwithstanding the foregoing, the Company shall not be required to furnish to the Holders any prospectus supplement
being prepared and filed solely to name new or additional selling stockholders unless such Holders or their controlling Person or custodian are named in such prospectus supplement. In addition, in the event that any Registration Statement is on Form
S-1 (or other form which does not permit incorporation by reference), the Company shall not be required to furnish to the Holders any prospectus supplement containing information included in 

  
 35 

 
a report or proxy statement filed under the Exchange Act that would be incorporated by reference in such Registration Statement if such Registration Statement were on Form S-3 (or other form
which permits incorporation by reference). The Company shall duly incorporate any comments made by Holders acting reasonably and received by the Company not later than two Trading Days prior to the filing of the Registration Statement, but shall not
be required to accept any such comments to which it reasonably objects. 
 (b) (i) Prepare and file with the Commission such amendments,
including post-effective amendments, to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Securities for its
Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus to be amended or
supplemented by any required Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to each
Registration Statement or any amendment thereto and, as promptly as reasonably possible provide the Holders true and complete copies of all correspondence from and to the Commission relating to such Registration Statement that pertains to the
Holders as selling stockholders but not any comments that would result in the disclosure to the Holders of material and non-public information concerning the Company; and (iv) comply in all material respects with the provisions of the
Securities Act and the Exchange Act with respect to the Registration Statements and the disposition of all Registrable Securities covered by each Registration Statement. 

(c) Notify the Holders as promptly as reasonably possible (and, in the case of (i)(A) below, not less than three Trading Days prior to such
filing) and (if requested by any such Person) confirm such notice in writing no later than one Trading Day following the day: (i)(A) when a Prospectus or any prospectus supplement (but only to the extent notice is required under Section 3(a)
above) or post-effective amendment to a Registration Statement is proposed to be filed; (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments
in writing on such Registration Statement (in which case the Company shall provide true and complete copies thereof and all written responses thereto to each of the Holders that pertain to the Holders as a selling stockholder or to the Plan of
Distribution, but not information which the Company believes would constitute material and non-public information); and (C) with respect to each Registration Statement or any post-effective amendment, when the same has been declared effective;
(ii) of any request by the Commission or any other Federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that pertains to the Holders as selling
stockholders or the Plan of Distribution; (iii) of the issuance by the Commission of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings
for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or
threatening of any Proceeding for such purpose; (v) of the occurrence of any event or passage of time that makes the financial statements included or incorporated by reference in a Registration Statement ineligible for inclusion or
incorporation by reference therein or any statement made in such Registration 

  
 36 

 
Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration
Statement, Prospectus or other documents so that, in the case of such Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the
Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; provided, that any and all of such
information shall remain confidential to each Holder until such information otherwise becomes public, unless disclosure by a Holder is required by law; provided, further, that notwithstanding each Holder’s agreement to keep such
information confidential, each such Holder makes no acknowledgement that any such information is material, non-public information. 
 (d)
Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from
qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment. 
 (e) If requested by
a Holder, furnish to each Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto and all exhibits to the extent reasonably requested by such Person (including those previously furnished or
incorporated by reference) promptly after the filing of such documents with the Commission; provided, that the Company shall have no obligation to provide any document pursuant to this clause that is available on the EDGAR system. 

(f) If requested by a Holder, promptly deliver to each Holder, without charge, as many copies of each Prospectus or Prospectuses (including
each form of prospectus) and each amendment or supplement thereto as such Persons may reasonably request. Subject to Section 7(d) hereof, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each
of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto. 

(g) Prior to any public offering of Registrable Securities, use its commercially reasonable efforts to register or qualify or cooperate with
the selling Holders in connection with the registration or qualification (or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or Blue Sky laws of those jurisdictions within the
United States as any Holder reasonably requests in writing to keep each such registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things necessary or advisable to enable
the disposition in such jurisdictions of the Registrable Securities covered by the Registration Statements; provided, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so
qualified or subject the Company to any material tax in any such jurisdiction where it is not then so subject. 

  
 37 

 (h) Cooperate with the Holders to facilitate the timely preparation and delivery of certificates
or book-entry statements representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statements, which certificates or book-entry statements shall be free, to the extent permitted by the Purchase Agreement, of
all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may request. 

(i) Upon the occurrence of any event contemplated by Section 3(c)(v), as promptly as reasonably possible, prepare a supplement or
amendment, including a post-effective amendment, to the affected Registration Statements or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document
so that, as thereafter delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading. 
 (j) The Company may require each selling Holder to furnish to the
Company a certified statement as to the number of shares of Common Stock beneficially owned by such Holder and any Affiliate thereof, the natural persons thereof that have voting and dispositive control over the shares and any other information with
respect to such Holder as the Commission requests. 
 4. Holder’s Obligations. Each Holder agrees, by acquisition of the
Registrable Securities, that no Holder shall be entitled to sell any of such Registrable Securities pursuant to a Registration Statement or to receive a Prospectus relating thereto, unless such Holder has furnished the Company with all material
information required to be set forth in the Purchaser Questionnaire and Selling Stockholder Questionnaire pursuant to the Purchase Agreement. Any sale of any Registrable Securities by any Holder pursuant to a Prospectus delivered by such Holder
shall constitute a representation and warranty by such Holder that the information regarding such Holder is as set forth in such Prospectus, and that such Prospectus does not as of the time of such sale contain any untrue statement of a material
fact regarding such Holder or omit to state any material fact regarding such Holder necessary to make the statements in such Prospectus, in the light of the circumstances under which they were made, not misleading, solely to the extent such facts
are based upon information regarding such Holder furnished in writing to the Company by such Holder for use in such Prospectus. 
 5.
Registration Expenses. All fees and expenses incident to the Company’s performance of or compliance with its obligations under this Agreement (excluding any underwriting discounts and selling commissions) shall be borne by the Company
whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without
limitation, fees and expenses (A) with respect to filings required to be made with the Principal Market on which the Common Stock is then listed for trading, and (B) in compliance with applicable state securities or Blue Sky laws),
(ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of printing prospectuses if the printing of prospectuses is reasonably requested by the holders of a majority of the
Registrable Securities included in the Registration Statement), (iii) messenger, 

  
 38 

 
telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, including with respect to the issuance of opinions required for the removal of securities legends
in the manner described in the Transaction Documents, (v) reasonable fees and disbursements of counsel to the Holders, in an amount not to exceed $35,000, (vi) Securities Act liability insurance, if the Company so desires such insurance,
and (vii) reasonable fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal
expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of
any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of
any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Holders. To the extent that underwriting discounts and selling commissions are incurred in connection with the sale of Registrable
Securities in an Underwritten Offering hereunder, such underwriting discounts and selling commissions shall be borne by the Holders of Registrable Securities sold pursuant to such Underwritten Offering, pro rata on the basis of
the number of Registrable Securities sold on their behalf in such Underwritten Offering. 
 6. Indemnification. 

(a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless
each Holder (and, in the case of the FF Investor, the FF Beneficial Investor), the officers, directors, agents, partners, members, stockholders and employees of each Holder (or the FF Beneficial Investor, as applicable), each Person who controls any
such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, agents, partners, members, stockholders and employees of each such controlling Person, to the fullest
extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable costs of preparation and reasonable attorneys’ fees) and expenses (collectively,
“Losses”), as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement
thereto (it being understood that the Holder has approved Annex A hereto for this purpose), or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein (in the case of any Prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that (1) such untrue statements, alleged
untrue statements, omissions or alleged omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or
such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in the Registration Statement, such Prospectus or such form of Prospectus or in any
amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or (2) in the case of an occurrence of an event of the type specified in Section 3(c)(ii)-(v), the use by such Holder
of an outdated or defective Prospectus after the Company has validly 

  
 39 

 
notified such Holder in writing (in accordance with Section 7(i) below) that the Prospectus is outdated or defective and prior to the receipt by such Holder of an Advice (as defined below)
or an amended or supplemented Prospectus, but only if and to the extent that following the receipt of the Advice or the amended or supplemented Prospectus the misstatement or omission giving rise to such Loss would have been corrected. The Company
shall notify the Holders promptly of the institution, threat or assertion of any Proceeding of which the Company is aware in connection with the transactions contemplated by this Agreement. 

(b) Indemnification by Holders. Each Holder shall, notwithstanding any termination of this Agreement, severally and not jointly,
indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, agents, partners, members, stockholders or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising solely out of or based solely upon: (x) for so long
as the Company is not eligible to use Form S-3 under the Securities Act for a primary offering in reliance on General Instruction I.B.1 of such form and the prospectus delivery requirements of the Securities Act apply to sales by such Holder, such
Holder’s failure to comply with the prospectus delivery requirements of the Securities Act or (y) any untrue statement of a material fact contained in any Registration Statement, any Prospectus, or any form of prospectus, or in any
amendment or supplement thereto, or arising solely out of or based solely upon any omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, or any form of prospectus or
supplement thereto, in light of the circumstances under which they were made) not misleading to the extent, but only to the extent that, (1) such untrue statements or omissions are based solely upon information regarding such Holder furnished
in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved
in writing by such Holder expressly for use in the Registration Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or
(2) in the case of an occurrence of an event of the type specified in Section 3(c)(ii)-(v), the use by such Holder of an outdated or defective Prospectus after the Company has validly notified such Holder in writing (in accordance with
Section 7(i) below) that the Prospectus is outdated or defective and prior to the receipt by such Holder of an Advice or an amended or supplemented Prospectus, but only if and to the extent that following the receipt of the Advice or the
amended or supplemented Prospectus the misstatement or omission giving rise to such Loss would have been corrected. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds
received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation. 
 (c) Conduct of
Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom
indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees
and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of 

  
 40 

 
its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not
subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party. 

An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to
assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the named parties to any such Proceeding (including any impleaded parties) include both such
Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in
which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and
such counsel shall be at the expense of the Indemnifying Party); provided, that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of attorneys at any time for all Indemnified Parties pursuant
to this Section 6(c). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior
written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on
claims that are the subject matter of such Proceeding. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in
connection with defense of such claim and litigation resulting therefrom. 
 All fees and expenses of the Indemnified Party (including
reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading Days
of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified
Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party is not entitled to indemnification hereunder). 

(d) Contribution. If a claim for indemnification under Section 6(a) or 6(b) is unavailable to an Indemnified Party (by reason of
public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to
reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such
Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in 

  
 41 

 
question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by,
such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any
Losses shall be deemed to include, subject to the limitations set forth in Section 6(c), any reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would
have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms. 

The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 6(d) were determined by pro
rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 6(d), no Holder shall be
required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such
Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 
 The indemnity and contribution
agreements contained in this Section 6 are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Purchase Agreement.

 7. Miscellaneous. 

(a) Remedies. The parties agree that, in the event of a breach of this Agreement, the parties will, in addition to being entitled to
exercise all rights granted by law and under this Agreement, including recovery of damages, be entitled to specific performance of its rights under this Agreement. The parties agree that monetary damages may not provide adequate compensation for any
losses incurred by reason of a breach of the provisions of this Agreement and hereby further agree that, in the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be
adequate. 
 (b) Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the
Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement. 
 (c)
Subsequent Registration Rights. Until the Initial Registration Statement required hereunder is declared effective by the Commission, the Company shall not enter into any agreement granting any registration rights with respect to
any of its securities to any Person without the written consent of Holders representing no less than a majority of the then outstanding Registrable Securities; provided, that this Section 7(c) shall not prohibit the Company from
fulfilling its obligations under any other registration rights agreements existing as of the date hereof. 

  
 42 

 (d) Discontinued Disposition. Each Holder agrees by its acquisition of such Registrable
Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(c), such Holder will forthwith discontinue disposition of such Registrable Securities under the Registration Statement
until such Holder’s receipt of the copies of the supplemented Prospectus and/or amended Registration Statement or until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus may be
resumed, and, in either case, has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement. The Company may provide appropriate stop orders
to enforce the provisions of this paragraph. 
 (e) Furnishing of Information. Each Holder shall furnish in writing to the Company
such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably requested by the Company to effect the registration of such Registrable
Securities and shall execute such customary and appropriate documents in connection with such registration as the Company may reasonably request. At least three business days prior to the filing of a Registration Statement, the Company shall provide
a substantially final draft of such Registration Statement proposed to be filed to each Holder whose name or holdings are referenced in such Registration Statement, for the purpose of ensuring that the information so provided by the Holder pursuant
to this Section 7(e) or as otherwise required by this Agreement is properly reflected in such Registration Statement proposed to be filed. 

(f) Piggy-Back Registrations. If at any time during the Effectiveness Period, except as contemplated by Section 2(b)
hereof, there is not an effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or the
account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection
with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to each Holder a written notice of such determination and, if within 15 days
after the date of such notice, any such Holder shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities such Holder requests to be registered; provided,
however, that the Company shall not be required to register any Registrable Securities pursuant to this Section 7(f) that are eligible for resale pursuant to Rule 144 promulgated under the Securities Act without volume limitation or that
are the subject of a then effective Registration Statement; provided, further, however, if there is not an effective Registration Statement covering all of the Registrable Securities during the Effectiveness Period, the Company
may file a registration statement with the Commission to register equity securities of the Company to be sold on a primary basis, provided that the Company does not sell any such shares until there is an effective Registration Statement covering all
of the Registrable Securities. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 7(f) prior to the effectiveness of such registration whether or not any Holder has elected to include
securities in such registration. 

  
 43 

 (g) Amendments and Waivers. No provision of this Agreement may be waived or amended with
respect to the Company and another party hereto except with the written consent of the Company and such other party and, in the case, of the FF Investor, the FF Beneficial Investor. The Company shall provide prior notice to all Holders and the FF
Beneficial Investor of any proposed waiver or amendment. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. 

(h) Termination of Registration Rights. For the avoidance of doubt, it is expressly agreed and understood that (i) in the event
that there are no Registrable Securities outstanding as of a Filing Date, then the Company shall have no obligation to file, cause to be declared effective or to keep effective any Registration Statement hereunder (including any Registration
Statement previously filed pursuant to this Agreement) and (ii) all registration rights granted to the Holders hereunder (including the rights set forth in Sections 7(c) and 7(f)), shall terminate in their entirety effective on the first date
on which there shall cease to be any Registrable Securities outstanding. If not previously terminated pursuant to the foregoing sentence, it is expressly agreed and understood that all registration rights granted to the Holder pursuant to this
Agreement shall terminate as to the Holder on the earlier of (a) such time following the date that is five (5) years following the date of this Agreement that the Holders own in the aggregate less than 25% of the number of Registrable
Securities that the Holders owned in the aggregate as of the date hereof (as adjusted for stock splits, combinations, dividends, recapitalizations and the like) and (b) the date that is ten (10) years following the date of this Agreement.

 (i) Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed
electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received
in the case of mail or courier, and addressed as follows: 
 if to the Company, to: 

Ardelyx, Inc. 
 34175 Ardenwood
Blvd., Suite 200 
 Fremont, California 94555 

Attention: Chief Executive Officer 

E-Mail: mraab@ardelyx.com 
 with
a copy (which shall not constitute notice) to: 
 Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park,
California 94025 
 Attention: Mark Roeder 

E-Mail: mark.roeder@lw.com 

  
 44 

			
	 If to a Purchaser:
	  	To the address set forth under such Purchaser’s name on the signature pages hereto
		
	If to any other Person who is then the registered Holder:	  	To the address of such Holder as it appears in the stock transfer books of the Company
		
	If the FF Beneficial Investor	  	To the address set forth under the FF Beneficial Investor’s name on the signature pages hereto

 or such other address as may be designated in writing hereafter, in the same manner, by such Person. 

(j) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of
each of the parties and shall inure to the benefit of each Holder. 
 (k) Execution and Counterparts. This Agreement may be executed
in any number of counterparts, each of which when so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement and shall become effective when counterparts have been signed by each party
and delivered to the other parties, it being understood that all parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such
signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile or “.pdf” signature were the original thereof. 

(l) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the
interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or
agents) shall be commenced exclusively in the state and federal courts sitting in the City of San Francisco. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of San Francisco for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via 

  
 45 

 
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. 

(m) Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law. 

(n) Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall
use their reasonable best efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 

(o) Use of Terms. The parties agree and acknowledge that when, in this Agreement, the Company is required to use its reasonable best
efforts to perform any covenant under this Agreement, such requirement shall not obligate the Company, in the reasonable judgment of the disinterested members of its Board of Directors, to perform any act that will have a material adverse effect on
the Company. 
 (p) Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise
affect the meaning hereof. 
 (q) Independent Nature of Investors’ Obligations and Rights. The obligations of each
Investor hereunder is several and not joint with the obligations of any other Investor hereunder, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor hereunder. The decision by each Investor
to purchase Shares (in the case of the FF Beneficial Investor and the FF Investor, by the FF Investor on behalf of the FF Beneficial Investor) pursuant to the Transaction Documents has been made independently of any other Investor. Nothing contained
herein or in any other agreement or document delivered at any closing, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Purchasers are in any way acting in concert with respect to such obligations or the transactions contemplated by this Agreement. Each Investor acknowledges that no other Purchaser has acted as agent for such
Purchaser in connection with making its investment hereunder and that no Investor will be acting as agent of such Investor in connection with monitoring its investment in the Shares or enforcing its rights under the Transaction Documents (other than
in the case of the FF Investor and the FF Beneficial Investor). Each Investor shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other
Investor to be joined as an additional party in any proceeding for such purpose. 

  
 46 

 (r) Assignment. The rights of the FF Investor hereunder may be assigned in whole or in
part to a Permitted Transferee (as defined in the FF Side Letter) only with all restrictions and obligations set forth in this Agreement; provided, however, that (i) the FF Investor shall, within five (5) days prior to such
assignment, furnish to the Company written notice of the name and address of such Permitted Transferee, details of its status as a Permitted Transferee and details of the Registrable Securities with respect to which such registration rights are
being assigned, (ii) the Permitted Transferee, prior to or simultaneously with such transfer or assignment, shall agree in writing to be subject to and bound by all restrictions and obligations set forth in this Agreement, and (iii) such
transfer or assignment shall be effective only if immediately following such transfer or assignment the further disposition of such Registrable Securities by the Permitted Transferee is restricted under the Securities Act and other applicable
securities law. 
 (s) Entire Agreement. This Agreement, the Purchase Agreement and in the case of the Company, the FF Investor and
the FF Beneficial Investor only, the FF Side Letter, contain the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous arrangements or understandings, whether written or
oral, with respect hereto and thereto. The provisions of the FF Side Letter will prevail over the provisions of this Agreement to the extent of any inconsistency. 

(t) The FF Investor Limitation of Liability. The FF Investor enters into and is liable under (a) this Agreement, (b) any
other document or agreement which the FF Investor may be required to provide under this Agreement and (c) any document or agreement executed by the Company or any other person as agent or attorney of the FF Investor under this Agreement only in
its capacity as custodian for the FF Beneficial Investor, and to the extent that it is actually indemnified by the FF Beneficial Investor. To the extent this paragraph operates to reduce the amounts for which the FF Investor would otherwise be
liable to any person, the FF Beneficial Investor will pay or procure the payment of such amounts to such person. 
 (u) Exercise of the
FF Investor’s rights. The Company acknowledges and agrees that the FF Beneficial Investor may cause the FF Investor to exercise rights of the FF Investor hereunder. 

[Signature pages follow] 

  
 47 

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
  

			
	ARDELYX, INC.
		
	By:	 	  

	Name:	 	Michael Raab
	Title:	 	President and Chief Executive Officer

  
 Signature Pages to
Registration Rights Agreement 

 ANNEX A 

PLAN OF DISTRIBUTION 
 The
selling stockholders and any of their pledgees, donees, transferees, assignees or other successors-in-interest may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common
stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market
price, at varying prices determined at the time of sale, or at negotiated prices. The selling stockholders may use one or more of the following methods when disposing of the shares or interests therein: 

 

	 	•	 	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	 	•	 	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; 

 

	 	•	 	through brokers, dealers or underwriters that may act solely as agents; 

  

	 	•	 	purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	 	•	 	an exchange distribution in accordance with the rules of the applicable exchange; 

  

	 	•	 	privately negotiated transactions; 

  

	 	•	 	through the writing or settlement of options or other hedging transactions entered into after the effective date of the registration statement of which this prospectus is a part, whether through an options exchange or
otherwise; 

  

	 	•	 	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	 	•	 	a combination of any such methods of disposition; and 

  

	 	•	 	any other method permitted pursuant to applicable law. 

 The selling stockholders may also sell
shares under Rule 144 or Rule 904 under the Securities Act of 1933, as amended, or Securities Act, if available, or Section 4(a)(1) under the Securities Act, rather than under this prospectus. 

Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to
exceed what is customary in the types of transactions involved. 

 The selling stockholders may, from time to time, pledge or grant a security interest in some or
all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell shares of common stock from time to time under this prospectus, or under a
supplement or amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders
under this prospectus. 
 Upon being notified in writing by a selling stockholder that any material arrangement has been entered into with a
broker-dealer for the sale of common stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, we will file a supplement to this prospectus, if required, pursuant to Rule
424(b) under the Securities Act, disclosing (i) the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares involved, (iii) the price at which such shares of common stock were sold,
(iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in
this prospectus, and (vi) other facts material to the transaction. In addition, upon being notified in writing by a selling stockholder that a donee or pledge intends to sell more than 500 shares of common stock, we will file a supplement to
this prospectus if then required in accordance with applicable securities law. 
 The selling stockholders also may transfer the shares of
common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 

In connection with the sale of the shares of common stock or interests in shares of common stock, the selling stockholders may enter into
hedging transactions after the effective date of the registration statement of which this prospectus is a part with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging
the positions they assume. The selling stockholders may also sell shares of common stock short after the effective date of the registration statement of which this prospectus is a part and deliver these securities to close out their short positions,
or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions after the effective date of the registration statement of which this prospectus is
a part with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 

The selling stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting
commissions or discounts under the Securities Act. The maximum commission or discount to be received by any member of the Financial Industry Regulatory Authority (FINRA) or independent broker-dealer will not be greater than 8% of the initial gross
proceeds from the sale of any security being sold. 

 We have advised the selling stockholders that they are required to comply with Regulation M
promulgated under the Securities Exchange Act of 1934, as amended, during such time as they may be engaged in a distribution of the shares. The foregoing may affect the marketability of the common stock. 

The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly
or through agents. We will not receive any of the proceeds from this offering. 
 We are required to pay all fees and expenses incident to
the registration of the shares. We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act or otherwise. 

We have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until
the earlier of (a) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or (b) the date on which the shares of common stock covered by this prospectus
may be sold or transferred by non-affiliates without any volume limitations or pursuant to Rule 144 of the Securities Act. 

 SCHEDULE OF EXCEPTIONS 

July 14, 2016 
 This
Schedule of Exceptions is being furnished by Ardelyx, Inc., a Delaware corporation (the “Company”), to the Investors (as defined in that certain Securities Purchase Agreement of even date herewith by and among the Company and such
Investors (the “Agreement”)) in connection with the execution and delivery of the Agreement, pursuant to Section 4 of the Agreement. Unless the context otherwise requires, all capitalized terms used in this Schedule of
Exceptions shall have the respective meanings ascribed to such terms in the Agreement. 
 This Schedule of Exceptions and the information,
descriptions and disclosures included herein is intended to set forth exceptions to the representations and warranties of the Company contained in the Agreement. The contents of all agreements and other documents referred to in a particular section
of this Schedule of Exceptions are incorporated by reference into such particular section as though fully set forth in such section. 
 None. 

 SCHEDULE 1 

Name 
 New Enterprise Associates 12, Limited Partnership

 New Enterprise Associates 15, L.P. 
 NEA 15 Opportunity Fund,
L.P. 
 Form of Affiliate Legend 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE HELD BY AN AFFILIATE OF THE ISSUER AS DEFINED IN RULE 144 PROMULGATED UNDER THE SECURITIES ACT OF 1933
AND MAY ONLY BE SOLD OR OTHERWISE TRANSFERRED IN COMPLIANCE WITH THE REQUIREMENTS OF RULE 144 OR PURSUANT TO A REGISTRATION STATEMENT UNDER SAID ACT OR AN EXEMPTION FROM SUCH REGISTRATION.”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]